Document:

exv10w6

[***]
Indicates text has been omitted from this Exhibit pursuant to a
confidential treatment request and has been filed separately with the
Securities and Exchange Commission.

Exhibit 10.6

4060.LICI.006 Harvard

Co-Exclusive License Agreement

Between

President and Fellows of Harvard College

And

Mycometrix Corporation

Effective as of October 15, 2000

Re:
Harvard Case [***]

In consideration of the mutual promises and covenants set forth below, the parties hereto
agree as follows:

Article I

Definitions

	 	 	As used in this Agreement, the following terms shall have the following meanings:
	 
	1.1	 	ACADEMIC RESEARCH PURPOSES: use of PATENT RIGHTS for academic research or other
not-for-profit scholarly purposes which are undertaken at a non-profit or governmental
institution that does not use the PATENT RIGHTS in the production or manufacture of products
for sale or the performance of services for a fee.
	 
	1.2	 	AFFILIATE: any entity which controls, is controlled by, or is under common control with a
party by ownership or control of at least fifty percent (50%) of the voting stock or other
ownership. Unless otherwise specified, the term LICENSEE includes AFFILIATES.
	 
	1.3	 	FIELD: use of PATENT RIGHTS to develop, manufacture, use, offer for sale, sell, or import
components and products in FIELD I and/or FIELD II:
	 
	 	 	FIELD I:
[***]
	 
	 	 	FIELD II:
[***]

1

 

	1.4	 	HARVARD: President and Fellows of Harvard College, a nonprofit Massachusetts educational
corporation having offices at the Office for Technology and Trademark Licensing, Holyoke
Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138.
	 
	1.5	 	LICENSED PROCESSES: the processes covered by at least one VALID CLAIM included within the
PATENT RIGHTS.
	 
	1.6	 	LICENSED PRODUCTS: products covered by at least one VALID CLAIM included within the PATENT
RIGHTS or products made or services provided in accordance with or by means of LICENSED
PROCESSES.
	 
	1.7	 	LICENSEE: Mycometrix Corporation, a corporation organized under the laws of Califonia having
its principal offices at 213 East Grand Avenue, South San Francisco, CA 94080.
	 
	1.8	 	NET SERVICE INCOME: SERVICE INCOME less LICENSEE’s actual direct and indirect cost for
research, development and/or services provided.
	 
	1.9	 	NET SALES: the amount actually received for sales, leases, or other transfers of LICENSED
PRODUCTS, less:

	 	(i)	 	customary trade, quantity or cash discounts and
non-affiliated brokers’ or agents’ commissions actually allowed and taken;
	 
	 	(ii)	 	amounts repaid or credited by reason of rejection or return;
	 
	 	(iii)	 	to the extent separately stated on purchase orders, invoices, or other
documents of sale, taxes levied on and/or other governmental charges made as to
production, sale, transportation, delivery or use and paid by or on behalf of
LICENSEE; and
	 
	 	(iv)	 	reasonable charges for delivery or transportation provided by third parties
and cost of insurance in transit, if separately stated.

	 	 	NET SALES also includes the fair market value of any non-cash consideration received by
LICENSEE for the sale, lease, or transfer of LICENSED PRODUCTS.
	 
	 	 	If a LICENSED PRODUCT is sold as a combination product containing the LICENSED PRODUCT and
one or more other components, NET SALES shall be calculated by multiplying the gross amount
invoiced for the sale of the combination product by the fraction A/A+B where A is the average
gross selling price of the LICENSED PRODUCT sold separately by LICENSEE and B is the average
gross selling price of such other components of the combination products sold separately by
LICENSEE during the relevant royalty payment period.

2

 

	 	 	In the event that LICENSEE grants a sublicensee hereunder, and receives payments based upon
SUBLICENSEE’s sales of LICENSED PRODUCTS, LICENSEE may upon approval from HARVARD (which
shall not be unreasonably withheld) modify the definition of NET SALES for the purposes of
calculating royalties payable to HARVARD on such SUBLICENSEE’s sales to be the same as the
definition of NET SALES on which such royalties to LICENSEE are calculated.
	 
	1.10	 	SERVICE INCOME: the total financial consideration received by LICENSEE for commercial
services performed on a fee-for-service basis using the LICENSED PRODUCTS or LICENSED
PROCESSES by LICENSEE under a contract with a third party, where such services are based
primarily on the use of fully functional LICENSED PRODUCTS or LICENSED PROCESSES (as
applicable) for their intended commercial use (such as, for example, where LICENSEE performs
commercial-scale genotyping services for a pharmaceutical company on a fee-for-service basis
using fully developed microfluidics chips comprising LICENSED PRODUCTS). SERVICE INCOME shall
not include amounts received in connection with research and/or development of LICENSED
PRODUCTS or LICENSED PROCESSES themselves.
	 
	1.11	 	PATENT RIGHTS: The applications and patents as listed in Appendix A of this Agreement, the
allowed claims of such applications, the inventions described and claimed therein, and any
divisions or continuations of the applications and patents as listed in Appendix A, and
specific claims of any continuations-in-part of such applications to the extent the specific
claims are directed to subject matter described in the applications and patents listed in
Appendix A in a manner sufficient to support such specific claims under 35 U.S.C., patents
issuing thereon or reissues thereof, and any and all foreign patents and patent applications
corresponding thereto, all to the extent owned or controlled by HARVARD.
	 
	1.12	 	SUBLICENSE INCOME: the amount paid to LICENSEE by a third party (other than an AFFILIATE of
LICENSEE) (a) for the sublicening of PATENT RIGHTS to a third party as well as (b) for the
related licensing of LICENSEE’s own patent rights or know-how or
LICENSEE’s in-licensed
non-HARVARD technologies, including but not limited to (i) license fees, (ii) milestone
payments, (iii) royalties, (iv) the fair market value in cash of any non-cash consideration
for such sublicense, and (v) in the event that LICENSEE receives any payment for equity in
consideration for the grant of sublicense rights that included a premium over the fair market
value of such equity, the amount of such premium. LICENSEE shall be responsible for
determining such fair market value with reasonable business judgment.
	 
	1.13	 	SUBLICENSEE: any non-AFFILIATE granted a sublicense of any of the rights HARVARD has granted
to LICENSEE under Section 3.1.
	 
	1.14	 	TERRITORY: Worldwide.

3

 

	1.15	 	VALID CLAIM: either (i) a claim of an issued patent that has not been held
unenforceable or invalid by an agency or a court of competent jurisdiction in any
unappealable or unappealed decision or (ii) a claim of a published, pending patent
application, which claim is substantially identical to a corresponding claim in a subsequently
issued patent having priority to the patent application.
	 
	1.16	 	The terms “Public Law 96-517” and “Public Law 98-620” include all amendments to those statutes.
	 
	1.17	 	The terms “sold” and “sell” include, without limitation, leases and other transfers and similar transactions.

Article II

Representations

	2.1	 	HARVARD is owner by assignment from [***], in the US and foreign patent applications
corresponding thereto, and in the inventions described and claimed therein. Inventorship
will be finalized in the near future.
	 
	2.2	 	HARVARD has authority to issue licenses under PATENT RIGHTS.
	 
	2.3	 	HARVARD is committed to the policy that ideas or creative works produced at HARVARD should
be used for the greatest possible public benefit, and believes that every reasonable
incentive should be provided for the prompt introduction of such ideas into public use, all
in a manner consistent with the public interest.
	 
	2.4	 	LICENSEE is prepared and intends to diligently develop the invention and to bring products
to market which are subject to this Agreement, specifically including one or more products in
the FIELD selected from a [***].
	 
	2.5	 	LICENSEE is desirous of obtaining a co-exclusive license in the FIELD and in the TERRITORY
in order to practice the PATENT RIGHTS in the United States and in certain foreign countries,
and to manufacture, use and sell in the commercial market the products made in accordance
therewith, and HARVARD is desirous of granting such a license to LICENSEE in accordance with
the terms of this Agreement.

Article III

Grant of Rights

	3.1	 	HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the terms and conditions
hereof, in the TERRITORY a co-exclusive commercial license under PATENT

4

 

	 	 	RIGHTS in FIELD I and in FIELD II to make and have made, to use and have used, to sell and
have sold, and to offer for sale and have offered for sale the LICENSED PRODUCTS, and to
practice the LICENSED PROCESSES, for the life of the PATENT RIGHTS. HARVARD will grant no
more than two commercial licenses in FIELD I at any time and will grant no more than two
commercial licenses in FIELD II at any time and HARVARD will not grant other licenses in the
FIELD except as required by HARVARD’s obligations in Section 3.2(a) or as permitted Section
3.2(b). Such co-exclusive license shall include the right to grant sublicenses under the
following circumstances: (i) LICENSEE can demonstrate that it has added significant value to
the PATENT RIGHTS to be sublicensed, and that such a sublicense also contains a substantial
and essentially simultaneous license of LICENSEE owned intellectual property, or (ii)
LICENSEE grants a sublicense under other HARVARD patent rights licensed exclusively to
LICENSEE which are dominated by PATENT RIGHTS, and such sublicense under PATENT RIGHTS is
necessary to practice such other HARVARD patent rights.
	 
	3.2	 	The granting and exercise of this license is subject to the following conditions:

	 	(a)	 	HARVARD’s “Statement of Policy in Regard to Inventions, Patents and Copyrights,”
dated August 10, 1998, Public Law 96-517, Public Law 98-620. In addition, this Agreement
is subject to HARVARD’s obligations under agreements with other sponsors of research,
provided that such obligations are not in conflict with the rights granted hereunder.
Any right granted in this Agreement greater than that permitted under Public Law 96-517,
or Public Law 98-620, shall be subject to modification as may be required to conform to
the provisions of those statutes.
	 
	 	(b)	 	HARVARD reserves the right to make and use, and grant to others non-exclusive
licenses to make and use solely for ACADEMIC RESEARCH PURPOSES the subject matter
described and claimed in PATENT RIGHTS.
	 
	 	(c)	 	LICENSEE shall use commercially reasonable efforts to effect introduction of the
LICENSED PRODUCTS into the commercial market as soon as practicable, consistent with
sound and reasonable business practice and judgment; thereafter, until the expiration
of this Agreement, LICENSEE shall endeavor to keep LICENSED PRODUCTS reasonably
available to the public.
	 
	 	(d)	 	At any time after three years from the effective date of this Agreement and as
HARVARD’s sole remedy for such non-performance, HARVARD may increase the license
maintenance royalty under Section 4.4 to [***] ($[***]) dollars each in
FIELD I and in FIELD II in year 2004 and [***] ($[***]) dollars each in FIELD
I and FIELD II per year each year beginning in 2005, if in
HARVARD’s reasonable
judgment, the Progress Reports furnished by LICENSEE do not demonstrate that LICENSEE
has satisfied at least one of the following conditions, which non-performance is not
cured within ninety (90) days following the written notification of such by HARVARD to
LICENSEE:

5

 

	 	(i)	 	has put the licensed subject matter into commercial use in at least one of
the countries hereby licensed, directly or through a sublicense, and is keeping
the licensed subject matter reasonably available to the public; or
	 
	 	(ii)	 	is engaged in research, development, manufacturing, marketing or
sublicensing activity appropriate to achieving 3.2(d)(i).

	 	(e)	 	In all sublicenses granted by LICENSEE hereunder, LICENSEE shall include a
requirement that the SUBLICENSEE use commercially reasonable efforts to bring the
subject matter of the sublicense into commercial use. LICENSEE shall further provide in
such sublicenses that such sublicenses are subject and subordinate to the terms and
conditions of this Agreement, except: (i) the SUBLICENSEE may not further sublicense;
and (ii) the rate of royalty on NET SALES paid by the SUBLICENSEE to the LICENSEE.
Copies of the relevant provisions of all sublicense agreements shall be provided
promptly to HARVARD. HARVARD agrees to maintain any information contained in such
provisions in confidence, except as otherwise required by law, however, HARVARD may
include in its usual reports annual amounts of royalties paid.
	 
	 	(f)	 	A license in any other field of use in addition to the FIELD shall be the
subject of a separate agreement and shall require LICENSEE’s submission of evidence,
satisfactory to HARVARD, demonstrating LICENSEE’s willingness and ability to develop
and commercialize in such other field of use the kinds of products or processes likely
to be encompassed in such other fields.
	 
	 	(g)	 	To the extent that federal funds are used to support research leading to a
patent or patent application in the PATENT RIGHTS, LICENSEE shall cause any LICENSED
PRODUCT produced for sale by LICENSEE or SUBLICENSEES in the United States to be
manufactured substantially in the United States during the period of exclusivity of
this license in the United States.

	3.4	 	All rights reserved to the United States Government and others under Public Law 96-517, and
Public Law 98-620, shall remain and shall in no way be affected by this Agreement.

Article IV

Royalties

	4.1	 	LICENSEE shall pay to HARVARD a non-refundable license
royalty fee in the sum of [***] dollars ($[***]) payable within thirty (30) days of the execution date of this
Agreement.
	 
	4.2	 	(a) In consideration of the right and license granted herein, LICENSEE shall pay to HARVARD
during the term of this Agreement a royalty of [***] percent ([***]) on NET SALES of LICENSED
PRODUCTS sold by LICENSEE.

6

 

	 	 	(b) In the event that a single LICENSED PRODUCT or LICENSED PROCESS is covered by HARVARD
intellectual property in addition to PATENT RIGHTS, which is licensed to LICENSEE under other
agreements as of the date of this Agreement, then the total royalty payment due HARVARD under all
such agreements including this Agreement shall be [***] percent ([***]) of NET SALES. LICENSEE shall
notify HARVARD of the identity of each license agreement that includes patent rights covering the
product or process, and HARVARD shall distribute the royalties evenly among such agreements.
	 
	 	 	(c) As consideration for the rights granted hereunder, LICENSEE shall pay to
HARVARD during the term of this Agreement a royalty in the form of stock of LICENSEE as follows:

	 	(i)	 	LICENSEE shall issue to HARVARD [***] shares of the Common Stock of LICENSEE (“Shares”) pursuant to the terms of a
mutually acceptable Stock Subscription Agreement, provided, however, that HARVARD shall
be subject to and enter into appropriate agreements and related documents as required of
other stockholders of LICENSEE.

(ii) HARVARD represents and warrants to LICENSEE that:

(1) HARVARD is acquiring the Shares for its own account for investment and not
with a view to, or for sale in connection with any distribution thereof, nor with
any present intention of distributing or selling the same; and HARVARD has no
present or contemplated agreement, undertaking, arrangement, obligation,
indebtedness or commitment providing for the disposition thereof.

(2) HARVARD has full power and authority to enter into and to perform this
Agreement in accordance with its terms.

(3) HARVARD has sufficient knowledge and experience in investing in companies
similar to LICENSEE so as to be able to evaluate the risks and merits of its
investment in LICENSEE and is able financially to bear the risks thereof.

(iii) Each certificate representing the Shares shall bear a legend
substantially in the following form:

7

 

“The shares represented by this certificate have not been registered under the Securities
Act of 1933 or any state securities law and they may not be sold or otherwise transferred
by any person, including a pledgee, unless (1) either (a) a registration statement with
respect to such shares shall be effective under the Securities Act of 1933, as amended,
or (b) the Corporation shall have received an opinion of counsel satisfactory to the
Corporation that an exemption from registration under such Act is then available, and (2)
there shall have been compliance with all applicable securities laws.”

“The shares represented by this certificate are subject to a mutually agree-upon Stock
Purchase and Right of First Refusal Agreement with this Corporation, a copy of which
Stock Purchase and Right of First Refusal Agreement is available for inspection at the
offices of the Corporation or may be made available upon request.”

The foregoing legend shall be removed from the certificates representing any Shares, at
the request of the holder thereof, at such time as they become eligible for resale
pursuant to the Securities Act of 1933, as amended.

If at any time prior to the time the Shares are eligible for resale pursuant to an
exemption from registration under the Securities Act of 1933, as amended, LICENSEE
proposes to register any of its Common Stock, under the Securities Act of 1933, except at
LICENSEE’s initial public offering or any offering pursuant to Forms S-4 or S-8, LICENSEE
shall offer HARVARD the opportunity to have its Shares registered under the registration
statement to be filed at such time. HARVARD will be offered the right to register its
Shares under the same terms, conditions and restrictions as other shareholders with
piggyback registration rights and the inclusion of any Shares in such registration
statement shall be subject to the approval of the underwriters of such offering

(iv) HARVARD’s ownership rights to Shares shall not be affected should the license
pursuant to this Agreement be converted to a non-exclusive one.

(d) In the case of sublicenses, LICENSEE shall also pay to HARVARD a royalty of [***] of
SUBLICENSE INCOME. If compensation for such a sublicense of PATENT RIGHTS is bundled with
compensation received for the sublicensing of the other HARVARD patent rights licensed to LICENSEE
under other agreements as of the date of this Agreement, LICENSEE
shall pay HARVARD only [***] of the total compensation received no matter how many license agreements from HARVARD
are involved. In such a case, LICENSEE shall notify HARVARD of the identity of each license
agreement involved and HARVARD shall distribute its [***] of

8

 

compensation equally among those license agreements, including this Agreement.

(e) LICENSEE shall pay HARVARD [***] of NET SERVICE INCOME. If SERVICE INCOME
is bundled with service income under another license to LICENSEE as of the date of this
Agreement, LICENSEE shall pay a royalty of [***] of NET SERVICE INCOME
received from each and every third party (“Third Party”) to which services are provided.
LICENSEE shall notify HARVARD of the identity of each license agreement involved in the
services and HARVARD shall distribute its [***] of compensation equally among
those license agreements, including this Agreement.

(f) If other co-exclusive licenses in the same FIELD and TERRITORY are granted after the
date this Agreement is executed, the above financial compensation shall not exceed the
financial compensation to be paid by other licensees in the same FIELD and TERRITORY during
the term of the co-exclusive license provided LICENSEE accepts any less favorable terms
included in such other license.

If stock is part of the financial compensation to be paid by other licensees in the same
FIELD and TERITORY, the fair market value of the stock shall be the same as the price per
share which other investors paid in the last round of financing unless the stock is publicly
traded.

	4.3	 	On sales between LICENSEE and its AFFILIATES for resale or incorporation into
products, the royalty shall be paid on the NET SALES of the AFFILIATE. On sales
between LICENSEE and sublicensees for resale, the royalty shall be paid on the
SUBLICENSE INCOME.
	 
	4.4	 	No later than January 1 of each calendar year indicated below, LICENSEE shall pay to
HARVARD the following non-refundable license maintenance royalty and/or advance on
royalties. Such payments shall be credited against running royalties due for that calendar
year and Royalty Reports shall reflect such a credit. Such payments shall not be credited
against milestone payments (if any) nor against royalties due for any subsequent calendar
year nor against such payments due under any other agreements with HARVARD.

	 	 	 	 	 	 	 	 	 
	 	 	FIELD I	 	FIELD II
	January 1, 2002
	 	 	[***]	 	 	 	[***]	 
	January 1, 2003
	 	 	[***]	 	 	 	[***]	 
	January 1, 2004
	 	 	[***]	 	 	 	[***]	 
	each year thereafter
	 	 	[***]	 	 	 	[***]	 

Article V

Reporting

	5.1	 	Prior to signing this Agreement, LICENSEE has provided to HARVARD a written business plan
under which LICENSEE intends to bring the subject matter of the licenses

9

 

	 	 	 	 	 
	 	 	granted hereunder into commercial use upon execution of this Agreement. Such plan includes
proposed marketing efforts.
	 
	5.2   	 	No later than sixty (60) days after June 30 of each calendar year, LICENSEE shall provide to
HARVARD a written annual Progress Report describing progress on research and development,
regulatory approvals, manufacturing, sublicensing, marketing and sales during the most recent
twelve (12) month period ending June 30 and plans for the forthcoming year. If multiple
technologies are covered by the license granted hereunder, the Progress Report shall provide
the information set forth above for each technology. If progress differs from that anticipated
in the plan required under Section 5.1, LICENSEE shall explain the reasons for the difference
and propose a modified plan for HARVARD’s review. LICENSEE shall also provide any reasonable
additional data HARVARD requires to evaluate LICENSEE’s performance.
	 
	5.3	 	LICENSEE shall report to HARVARD the date of first sale of LICENSED PRODUCTS (or results of
LICENSED PROCESSES) in each country within thirty (30) days of occurrence.
	 
	5.4	 	(a)	LICENSEE shall submit to HARVARD within sixty (60) days after each calendar
half year ending June 30 and December 31, a Royalty Report setting forth for such half
year at least the following information:
	 

	 	 	 	(i)	the number of LICENSED PRODUCTS sold by LICENSEE in each country;
	 
	 	 	 	(ii)	total billings and amounts actually received for such LICENSED PRODUCTS;
	 
	 	 	 	(iii)	an accounting for all LICENSED PROCESSES used or sold;
	 
	 	 	 	(iv)	deductions applicable to determine the NET SALES thereof;
	 
	 	 	 	(v)	the amount of SERVICE INCOME received by LICENSEE and an accounting
of all deductions to yield NET SERVICE INCOME;
	 
	 	 	 	(vi)	the amount of SUBLICENSE INCOME received by LICENSEE; and
	 
	 	 	 	(vii) 	the amount of royalty due thereon, or, if no royalties are due to
HARVARD for any reporting period, the statement that no royalties are due.
	 

	 	 	 	Such report shall be certified as correct by an officer of LICENSEE and shall include a
detailed listing of all deductions from royalties.
	 

	 	 	(b)	LICENSEE shall pay to HARVARD with each such Royalty Report the amount of
royalty due with respect to such half year. If multiple technologies are covered by the
license granted hereunder, LICENSEE shall specify which PATENT RIGHTS are utilized for
each LICENSED PRODUCT and LICENSED PROCESS included in the Royalty Report.

10

 

	 	(c)	 	All payments due hereunder shall be deemed received when funds are credited to
HARVARD’s bank account and shall be payable by check or wire transfer in United States
dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion
rate existing in the United States (as reported in the New York Times or the Wall
Street Journal) on the last working day of each royalty period. No transfer, exchange,
collection or other charges shall be deducted from such payments.
	 
	 	(d)	 	All such reports shall be maintained in confidence by HARVARD except as required
by law; however, HARVARD may include in its usual reports annual amounts of royalties
paid.
	 
	 	(e)	 	Late payments shall be subject to a charge of one and one-half percent (1.5%)
per month, or $250, whichever is greater.

	5.5	 	In the event of acquisition, merger, change of corporate name or change in make-up,
organization, or identity, LICENSEE shall notify HARVARD in writing within thirty
(30) days of such event.
	 
	5.6	 	If by law, regulation or fiscal policy of a particular country, conversion into United
States
dollars or transfer of funds of a convertible currency to the United States is restricted or
forbidden, LICENSEE shall give HARVARD prompt notice in writing and shall pay the
royalty and other amounts due through such means or methods as are lawful in such
country as HARVARD may reasonably designate. Failing the designation by HARVARD
of such lawful means or methods within thirty (30) days after such notice is given to
HARVARD, LICENSEE shall deposit such royalty or other payment in local currency to
the credit of HARVARD in a recognized banking institution designated by HARVARD,
or if none is designated by HARVARD within the thirty (30) day period described above,
in a recognized banking institution selected by LICENSEE and identified in a written
notice to HARVARD by LICENSEE, and such deposit shall fulfill all obligations of
LICENSEE to HARVARD with respect to such royalties. When in any country in which
the law or regulations prohibit both the transmittal and deposit of royalties on sales in
such
country, royalty payments shall be suspended for as long as such prohibition is in effect,
and as soon as such prohibition ceases to be in effect, all royalties which LICENSEE
would have been under obligation to transmit or deposit, but for the prohibition, shall be
deposited or transmitted promptly to the extent allowable.

Article VI

Record Keeping

	6.1	 	LICENSEE shall keep, and shall require its SUBLICENSEES to keep, accurate records (together
with supporting documentation) of LICENSED PRODUCTS made, used or sold under this Agreement,
and SERVICE INCOME and SUBLICENSE INCOME received by LICENSEE under this Agreement,
appropriate to determine the amount of royalties due to HARVARD hereunder. Such records shall
be retained for three (3) years following the end of the reporting period to which they
relate. For such three year period, they shall be

11

 

	 	 	available during normal business hours upon reasonable advance notice for examination by a
certified public accountant selected by HARVARD, and reasonably acceptable to LICENSEE, for
the sole purpose of verifying reports and payments hereunder. In conducting examinations
pursuant to this Section 6.1, HARVARD’s accountant shall have access to all records which
HARVARD reasonably believes to be relevant to the calculation of royalties under Article IV.
HARVARD agrees to maintain any information contained in such records in confidence, except
as otherwise required by law and except information in regarding the amount of royalties
due.
	 
	6.2	 	HARVARD’s accountant shall not disclose to HARVARD any information other than information
relating to the accuracy of reports and payments made hereunder.
	 
	6.3	 	Such examination by HARVARD’s accountant shall be at
HARVARD’s expense, except that if such
examination shows an underreporting or underpayment in excess of five percent (5%) for any
twelve (12) month period, then LICENSEE shall pay the cost of such examination as well as any
additional sum that would have been payable to HARVARD had the LICENSEE reported correctly,
plus interest on said sum at the rate of one and one-half percent (1.5%) per month.

Article VII

Domestic and Foreign Patent Filing and Maintenance

	

	7.1	 	Upon execution of this Agreement, LICENSEE shall reimburse HARVARD for fifty percent (50%)
of all reasonable expenses HARVARD has incurred for the preparation, filing, prosecution,
maintenance and counseling with respect to PATENT RIGHTS. Such
expenses total [ *  *  * ] as
of October 1, 2000. Thereafter, LICENSEE shall reimburse HARVARD
for fifty percent (50%)  of
all such future reasonable expenses prior to termination of this Agreement upon receipt of
invoices from HARVARD.
	

	 
	7.2	 	HARVARD shall be responsible for the preparation, filing, prosecution and maintenance of any
and all patent applications and patents included in PATENT RIGHTS. HARVARD will instruct
counsel to directly notify HARVARD and LICENSEE and provide them copies of any official
communications from the United States and foreign patent offices relating to said prosecution,
and to provide LICENSEE with advance draft copies of all relevant communications to the
various patent offices, so that LICENSEE may be informed and apprised of the continuing
prosecution of patent applications in PATENT RIGHTS. LICENSEE shall have reasonable
opportunities to participate in decision making on all key decisions affecting filing,
prosecution and maintenance of patents and patent applications in PATENT RIGHTS. HARVARD will
use reasonable efforts to incorporate LICENSEE’s reasonable suggestions regarding said
prosecution. HARVARD shall use all reasonable efforts to amend any patent application to
include claims reasonably requested by LICENSEE to protect LICENSED PRODUCTS.
	 
	7.3	 	HARVARD and LICENSEE shall cooperate fully in the preparation, filing, prosecution and
maintenance of PATENT RIGHTS and of all patents and patent applications licensed to LICENSEE
hereunder, executing all papers and instruments or requiring members of

12

 

	 	 	HARVARD to execute such papers and instruments so as to enable HARVARD to apply for, to
prosecute and to maintain patent applications and patents in
HARVARD’s name in any country.
Each party shall provide to the other prompt notice as to all matters which come to its
attention and which may affect the preparation, filing, prosecution or maintenance of any
such patent applications or patents.
	 
	7.4	 	LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty (60) days
written notice to HARVARD. Such notice shall not relieve LICENSEE from responsibility to
reimburse HARVARD for patent-related expenses incurred prior to the expiration of the (60)
day notice period.
	 
	

	7.5	 	If HARVARD elects not to prosecute or maintain any of the patents or patent applications
relating to PATENT RIGHTS or any portion thereof in any country, LICENSEE shall be given
sufficient notice of HARVARD’s decision so that LICENSEE may request that HARVARD continue
prosecuting or maintaining such patents or patent applications, at
LICENSEE’s expense. If
HARVARD elects not to prosecute or maintain such patents or patent applications after such
request by LICENSEE, then LICENSEE shall have the right, but not the obligation, at its own
expense to prosecute and maintain such patents and patent applications or portion thereof in
such country and in HARVARD’s name. If LICENSEE assumes 100% of the costs to file, prosecute,
and maintain certain patents and patent applications relating to the PATENT RIGHTS pursuant to
this Section 7.5, and, if HARVARD licenses the PATENT RIGHTS to one or more co-exclusive
licensees designated in Section 3.1 after such time, then HARVARD will credit LICENSEE with
the costs LICENSEE has paid in excess of 50% if one other licensee, due for the preparation,
filing, prosecution and maintenance of patents and patent applications relating to PATENT
RIGHTS pursuant to Section 7.1 above.
	

	 
	7.6	 	If LICENSEE can demonstrate that it is not being adequately informed or apprised of the
continuing prosecution of patents or patent applications in PATENT RIGHTS, or that it is not
being provided with reasonable opportunities to participate in decision making or that its
interests are not being adequately protected, LICENSEE shall be entitled to engage, at
LICENSEE’s expense, independent patent counsel to review and evaluate patent prosecution and
filing of patents and patent applications included in PATENT RIGHTS.

Article VIII

Infringement

	8.1	 	With respect to any PATENT RIGHTS that are licensed to LICENSEE pursuant to this Agreement,
LICENSEE shall have the right to prosecute in its own name and at its own expense any
infringement of such patent. HARVARD agrees to notify LICENSEE promptly of each infringement
of such patents of which HARVARD, as applicable, is or becomes aware. Before LICENSEE
commences an action with respect to any infringement of such patents, LICENSEE shall give
careful consideration to the views of HARVARD and to potential effects on the public interest
in making its decision whether or not to sue.

13

 

	8.2	 	LICENSEE acknowledges that other co-exclusive licensees of PATENT RIGHTS designated
in Section 3.1 shall have rights identical to LICENSEE to prosecute infringers and that co-
exclusive licensees will be bound by the identical terms of this Section 8.2. In any
prosecution instigated by LICENSEE and in which HARVARD, as necessary, is also named
plaintiff as owner of the PATENT RIGHTS, LICENSEE must notify other co-exclusive
licensees of the existence of such legal action and allow other co-exclusive licensees to join
as a plaintiff upon co-exclusive licensees’ request. In addition, in the event other co-
exclusive licensees instigate an infringement prosecution, LICENSEE hereby consents to
being joined as a plaintiff in such suit solely for the purpose of procuring standing to bring
the action and at the sole expense of the instigating co-exclusive licensee. To the extent that
LICENSEE desires to participate in any strategic decisions affecting the prosecution of the
action brought by other co-exclusive licensees, LICENSEE acknowledges that it and co-
exclusive licensees will necessarily have to reach a mutual agreement concerning litigation
expenses and strategy. In no event shall HARVARD incur any liability or expense in
connection with any action of co-exclusive licensees, joint or otherwise.
	 
	 	 	During any such litigation, HARVARD will agree to not license any defendant or accused
infringer of the PATENT RIGHTS in the litigation, without LICENSEE’s prior written consent.

	 	 	 	 	 
	8.3

	 	(a)
	 	If LICENSEE elects to commence an action as described above, HARVARD may, to
the extent permitted by law, elect to join as parties in that action. Regardless of
whether HARVARD elects to join as parties, HARVARD shall cooperate fully with LICENSEE
in connection with any such action.
	 
	 	 	 	 
	 

	 	(b)
	 	HARVARD agrees to join as a party in any action if required by law to do so in
order to bring an action under the PATENT RIGHTS.
	 
	 	 	 	 
	 

	 	(c)
	 	LICENSEE shall reimburse HARVARD for any costs incurs with LICENSEE’s approval,
including reasonable attorneys’ fees, as part of an action brought by LICENSEE,
irrespective of whether HARVARD becomes a co-plaintiff.

	

	8.4	 	If LICENSEE elects to commence an action as described above, LICENSEE may deduct
from its royalty payments to HARVARD with respect to the patent(s) subject to suit an
amount not exceeding fifty percent (50%) of LICENSEE’s expenses and costs of such
action, including reasonable attorneys’ fees; provided, however, that such reduction shall
not exceed fifty percent (50%) of the total royalty due to HARVARD with respect to the
patent(s) subject to suit for each calendar year. If such fifty percent (50%) of
LICENSEE’s expenses and costs exceeds the amount of royalties deducted by LICENSEE
for any calendar year, LICENSEE may to that extent reduce the royalties due to
HARVARD from LICENSEE in succeeding calendar years, but never by more than fifty percent (50%) of
the total royalty due in any one year with respect to the patent(s) subject
to suit.
	

14

 

	8.5	 	No settlement, consent judgment or other voluntary final disposition of the suit may be
entered into without the prior written consent of HARVARD which consent shall not be
unreasonably withheld.
	

	 
	8.6	 	Recoveries or reimbursements from actions commenced by LICENSEE pursuant to this Article
shall first be applied to reimburse LICENSEE, HARVARD for litigation costs not paid from
royalties and then to reimburse HARVARD for royalties deducted by LICENSEE pursuant to Section
8.4. Any remaining recoveries or reimbursements shall be shared as follows:

	 	(a)	 	If the amount is lost profits or lost royalties, LICENSEE shall receive an
amount equal to the damages the court determines LICENSEE has suffered as a result of
the infringement less the amount of any royalties that would have been due HARVARD on
sales of LICENSED PRODUCTS lost by LICENSEE as a result of the infringement had
LICENSEE made such sales, and HARVARD shall receive an amount equal to the royalties it
would have received if such sales had been made by LICENSEE, and
	 
	 	(b)	 	As to awards other than lost profits or lost royalties, fifty
percent (50%)
to LICENSEE and fifty percent (50%) to HARVARD.
	 
	 	(c)	 	If two or more co-exclusive licensees undertake the suit, the provision of this
Section 8.6 will be modified to take into account each co-exclusive licensee’s expenses
and lost profits.
	

	8.7	 	If LICENSEE elects not to exercise its right to prosecute an infringement of the PATENT
RIGHTS pursuant to this Article, HARVARD may do so at its own expense, controlling
such action and retaining all recoveries therefrom. LICENSEE shall cooperate fully with
HARVARD in connection with any such action.
	 
	8.8	 	If a declaratory judgment action is brought naming LICENSEE as a defendant and
alleging invalidity of any of the PATENT RIGHTS, HARVARD may elect to take over
the sole defense of the action at its own expense. LICENSEE shall cooperate fully with
HARVARD in connection with any such action. HARVARD shall consult with
LICENSEE regarding such defense.

Article IX

Termination of Agreement

	9.1	 	This Agreement, unless terminated as provided herein, shall remain in effect until the last
patent or patent application in PATENT RIGHTS has expired or been abandoned.
	 
	9.2	 	HARVARD may terminate this Agreement as follows:

	 	(a)	 	If LICENSEE does not make a payment due hereunder and fails to cure such
non-payment (including the payment of interest in accordance with Section 5.4(e)) within

15

 

	 	 	 	thirty (30) days after the date of notice in writing of such non-payment by HARVARD.
	 
	 	(b)	 	If LICENSEE defaults in its obligations under Sections 10.3(c) and 10.3(d) to
procure and maintain insurance.
	 
	 	(c)	 	If LICENSEE shall become insolvent, shall make an assignment for the benefit of
creditors, or shall have a petition in bankruptcy filed for or against it. Such
termination shall be effective immediately upon HARVARD giving written notice to
LICENSEE.
	 
	 	(d)	 	If an examination by HARVARD’s accountant pursuant to Article V shows an
underreporting or underpayment by LICENSEE in excess of twenty percent (20%) for any
twelve (12) month period, provided that such underreporting or underpayment is not
determined to be inadvertent or the result of an honest mistake.
	 
	 	(e)	 	If LICENSEE is convicted of a felony relating to the manufacture, use, or sale
of LICENSED PRODUCTS.
	 
	 	(f)	 	Except as provided in Subsections (a), (b), and (c) above, if LICENSEE defaults
in the performance of any material obligations under this Agreement and the default has
not been remedied within forty-five (45) days after the date of notice in writing of
such default by HARVARD.

	9.3	 	LICENSEE shall provide, in all sublicenses granted by it under this Agreement, that
LICENSEE’s interest in such sublicenses shall at HARVARD’s option terminate or be assigned to
HARVARD upon termination of this Agreement; however, LICENSEE shall have the option to
nominate one of its sublicensees as a substitute for LICENSEE. The proposed substitute must
(i) have a net worth of at least equivalent to the net worth LICENSEE had as of the date of
this Agreement and (ii) have available resources and sufficient scientific, business and other
expertise comparable to LICENSEE in order to satisfy its obligations under this Agreement. At
least sixty (60) days prior to termination of this Agreement, LICENSEE shall provide HARVARD
with written notice of LICENSEE’s nominee together with documentation sufficient to
demonstrate the requirements set forth in subparagraphs (i) and (ii) above for HARVARD’s
approval, which shall not be unreasonably withheld. HARVARD shall notify LICENSEE in writing
of its decision prior to termination of this Agreement. If HARVARD approves LICENSEE’s
nominee, LICENSEE shall assign this Agreement to its nominee and its nominee shall accept the
assignment no later than thirty (30) days after the termination date of this Agreement.
	 
	 	 	In the event that HARVARD disapproved LICENSEE’s first nominee, prior to the termination date
of this Agreement, LICENSEE shall have the option to nominate one of its other sublicensees
for HARVARD’s approval which shall not be unreasonably withheld.

16

 

	9.4	 	LICENSEE may terminate this Agreement by giving ninety (90) days advance written notice
of termination to HARVARD. Upon termination, LICENSEE shall submit a final Royalty Report to
HARVARD and any royalty payments and unreimbursed patent expenses invoiced by HARVARD shall
become immediately payable.
	 
	9.5	 	Sections 6.1, 6.2, 6.3, 7.1, 9.4, 9.5, 10.2, 10.3, 10.4, and 10.7 of this Agreement shall
survive termination.

Article X

General

	10.1	 	HARVARD does not warrant the validity of the PATENT RIGHTS licensed hereunder and make no
representations whatsoever with regard to the scope of the licensed PATENT RIGHTS or that such
PATENT RIGHTS may be exploited by LICENSEE, an AFFILIATE, or SUBLICENSEE without infringing
other patents, provided, however, HARVARD represents that it has no knowledge of any facts or
circumstances as of the execution date of this Agreement that would render any of the PATENT
RIGHTS invalid or unenforceable. HARVARD represents and warrants, to the best of its
knowledge, that HARVARD owns all right, title and interest in and to the PATENT RIGHTS.
	 
	10.2	 	HARVARD EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES AND MAKES NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS OR
INFORMATION SUPPLIED BY HARVARD, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS
AGREEMENT.

	 
	10.3	 	(a)	LICENSEE shall indemnify, defend and hold harmless HARVARD and its current or
former directors, governing board members, trustees, officers, faculty, medical and
professional staff, employees, students, and agents and their respective successors, heirs
and assigns (collectively, the “INDEMNITEES”), from and against any claim, liability, cost,
expense, damage, deficiency, loss or obligation of any kind or nature (including, without
limitation, reasonable attorney’s fees and other costs and expenses of litigation)
(collectively, “Claims”), based upon, arising out of, or otherwise relating to this
Agreement, including without limitation any cause of action relating to product liability
concerning any product, process, or service made, used or sold pursuant to any right or
license granted under this Agreement, provided, however, that such indemnification shall not
apply to any liability, damage, loss, or expense to the extent directly attributable to the
negligent activities, reckless misconduct or intentional misconduct of Indemnitees.
	 	 	(b)	Each Indemnitee that intends to claim indemnification under Section 10.3(a)
shall promptly notify LICENSEE of any claim or action in respect of which the
Indemnitee intends to claim such indemnification, and LICENSEE shall assume the defense
thereof with counsel mutually satisfactory to LICENSEE and HARVARD. The failure to
deliver notice to LICENSEE within a reasonable time after the

17

 

	 	 	 	commencement of any such claim or action, if materially prejudicial to its ability to defend
such action, shall relieve LICENSEE of any liability to the Indemnitee under Section 10.3(a)
with respect to such action, but the omission so to deliver notice to LICENSEE will not
relieve it of any liability that it may have to any Indemnitee otherwise than under Section
10.3(a). HARVARD and any other Indemnitee, and their respective employees and agents, shall
cooperate fully with LICENSEE and its legal representatives in the investigation of any claim
or action covered by the indemnification under Section 10.3(a).
	

	 
	 	(c)	 	Beginning at the time any such product, process or service is being commercially distributed
or sold (other than for the purpose of obtaining regulatory approvals) by LICENSEE or by a
SUBLICENSEE, AFFILIATE or agent of LICENSEE, LICENSEE shall, at its sole cost and expense,
procure and maintain commercial general liability insurance in amounts not less than
$2,000,000 per incident and $2,000,000 annual aggregate and naming the Indemnitees as
additional insureds. During clinical trials of any such product, process or service, LICENSEE
shall, at its sole cost and expense, procure and maintain commercial general liability
insurance in such equal or lesser amount as HARVARD shall require, naming the Indemnitees as
additional insureds. Such commercial general liability insurance shall provide: (i) product
liability coverage; and (ii) broad form contractual liability coverage for LICENSEE’s
indemnification under this Agreement. If LICENSEE elects to self-insure all or part of the
limits described above (including deductibles or retentions which are
in excess of $250,000
annual aggregate) such self-insurance program must be acceptable to HARVARD and the Risk
Management Foundation of the Harvard Medical Institutions, Inc. in their sole discretion. The
minimum amounts of insurance coverage required shall not be construed to create a limit of
LICENSEE’s liability with respect to its indemnification under this Agreement.
	

	 
	 	(d)	 	LICENSEE shall provide HARVARD with written evidence of such insurance upon request of
HARVARD. LICENSEE shall provide HARVARD with written notice at least fifteen (15) days prior
to the cancellation, non-renewal or material change in such insurance; if LICENSEE does not
obtain replacement insurance providing comparable coverage within such fifteen (15) day
period, HARVARD shall have the right to terminate this Agreement effective at the end of such
fifteen (15) day period without notice or any additional waiting periods.
	 
	 	(e)	 	LICENSEE shall maintain such commercial general liability insurance beyond the expiration or
termination of this Agreement during: (i) the period that any product, process, or service,
relating to, or developed pursuant to, this Agreement is being commercially distributed or
sold by LICENSEE or by a SUBLICENSEE, AFFILIATE or agent of LICENSEE; and (ii) a reasonable
period after the period referred to in Subsection (e)(i) above which in no event shall be
less than fifteen (15) years.

18

 

	10.4	 	LICENSEE shall not use HARVARD’s name or insignia, or any adaptation of them, or the
name of any of HARVARD’s inventors in any advertising, promotional or sales literature
without the prior written approval of HARVARD.
	 
	10.5	 	Without the prior written approval of HARVARD in each instance, neither this Agreement nor
the rights granted hereunder shall be transferred or assigned in whole or in part by LICENSEE
to any person whether voluntarily or involuntarily, by operation of law or otherwise, except
that each of LICENSEE and its AFFILIATES may assign this Agreement in connection with a
merger, consolidation or sale or transfer of all or substantially all of its assets. This
Agreement shall be binding upon the respective successors, legal representatives and assignees
of HARVARD and LICENSEE.
	 
	10.6	 	The interpretation and application of the provisions of this Agreement shall be governed by
the laws of the Commonwealth of Massachusetts.
	 
	10.7	 	LICENSEE shall comply with all applicable laws and regulations. In particular, it is
understood and acknowledged that the transfer of certain commodities and technical data is
subject to United States laws and regulations controlling the export of such commodities and
technical data, including all Export Administration Regulations of the United States
Department of Commerce. These laws and regulations among other things, prohibit or require a
license for the export of certain types of technical data to certain specified countries.
LICENSEE hereby agrees and gives written assurance that it will comply with all United States
laws and regulations controlling the export of commodities and technical data, that it will
be solely responsible for any violation of such by LICENSEE or its AFFILIATES or
SUBLICENSEES, and that it will defend and hold HARVARD, CHILDREN, and MIT harmless in the
event of any legal action of any nature occasioned by such violation.
	 
	10.8	 	LICENSEE agrees: (i) to obtain all regulatory approvals required for the manufacture and
sale of LICENSED PRODUCTS and LICENSED PROCESSES; and (ii) to utilize appropriate patent
marking on such LICENSED PRODUCTS. LICENSEE also agrees to register or record this Agreement
as is required by law or regulation in any country where the license is in effect.
	 
	10.9	 	Any notices to be given hereunder shall be sufficient if signed by the party (or party’s
attorney) giving same and either: (i) delivered in person; (ii) mailed certified mail return
receipt requested; or (iii) faxed to other party if the sender has evidence of successful
transmission and if the sender promptly sends the original by ordinary mail, in any event to
the following addresses:
	 
	 	 	If to LICENSEE:

Mycometrix Corporation

213 E. Grand Ave.

South San Francisco, CA 94080

Attention:

Fax: (650)-

19

 

	 	 	 	 
	 	 	If to HARVARD:
	 	 	 	Office for Technology and Trademark Licensing

Harvard University

Holyoke Center, Suite 727

1350 Massachusetts Avenue

Cambridge, MA 02138

Fax: (617) 495-9568
	 

	 	 	By such notice either party may change their address for future notices.
	 
	 	 	Notices delivered in person shall be deemed given on the date delivered. Notices sent by fax
shall be deemed given on the date faxed. Notices mailed shall be deemed given on the date
postmarked on the envelope.
	 		 
	10.10	 	Should a court of competent jurisdiction later hold any provision of this Agreement to be
invalid, illegal, or unenforceable, and such holding is not reversed on appeal, it shall be
considered severed from this Agreement. All other provisions, rights and obligations shall
continue without regard to the severed provision, provided that the remaining provisions of
this Agreement are in accordance with the intention of the parties.
	 
	10.11	 	In the event of any controversy or claim arising out of or relating to any provision of this
Agreement or the breach thereof, the parties shall try to settle such conflict amicably
between themselves. Subject to the limitation stated in the final sentence of this Section
10.11, any such conflict which the parties are unable to resolve promptly shall be settled
through arbitration conducted in accordance with the rules of the American Arbitration
Association. The demand for arbitration shall be filed within a reasonable time after the
controversy or claim has arisen, and in no event after the date upon which institution of
legal proceedings based on such controversy or claim would be barred by the applicable statute
of limitation. Such arbitration shall be held in Boston, Massachusetts. The award through
arbitration shall be final and binding. Either party may enter any such award in a court
having jurisdiction or may make application to such court for judicial acceptance of the award
and an order of enforcement, as the case may be. Notwithstanding the foregoing, either party
may, without recourse to arbitration, assert against the other party a third-party claim or
cross-claim in any action brought by a third party, to which the subject matter of this
Agreement may be relevant.
	 		 
	10.12	 	This Agreement constitutes the entire understanding between the parties and neither party
shall be obligated by any condition or representation other than those expressly stated
herein or as may be subsequently agreed to by the parties hereto in writing.

[The remainder of this page is intentionally blank.]

20

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly
authorized representatives.

	 	 	 	 	 
	President And Fellows	 	 	 	Mycometrix Corporation
	of Harvard College	 	 	 	 
	 	 	 	 	 
	/s/ Joyce Brinton	 	 	 	/s/ Gajus Worthington
	 	 	 	 	 
	Joyce Brinton, Director	 	 	 	 
	Office for Technology and	 	 	 	President
	Trademark Licensing	 	 	 	 
	 	 	 	 	 
	12/7/00	 	 	 	12/10/00
	 	 	 	 	 
	Date	 	 	 	Date

21

 

Appendix A

The following comprise PATENT RIGHTS:

[ *  *  * ]

[ *  *  * ]

22exv10w9

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 10.9

 

MASTER CLOSING AGREEMENT

By and Among

FLUIDIGM CORPORATION,

a California corporation,

OCULUS PHARMACEUTICALS, INC.,

a Delaware corporation,

and

THE UAB RESEARCH FOUNDATION

dated

March 7, 2003

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	ARTICLE I DEFINITIONS	 	 	1	 
	 
	 	1.1	 	“Affiliate”	 	 	1	 
	 
	 	1.2	 	“Ancillary Documents”	 	 	2	 
	 
	 	1.3	 	“Assigned Rights”	 	 	2	 
	 
	 	1.4	 	“Cash Consideration”	 	 	2	 
	 
	 	1.5	 	“Closing”	 	 	2	 
	 
	 	1.6	 	“Closing Cash Consideration”	 	 	2	 
	 
	 	1.7	 	“Closing Date”	 	 	2	 
	 
	 	1.8	 	“Encumbrances”	 	 	2	 
	 
	 	1.9	 	“Fluidigm Series C Preferred Stock”	 	 	2	 
	 
	 	1.10	 	“License Agreement”	 	 	2	 
	 
	 	1.11	 	“New License Agreement”	 	 	2	 
	 
	 	1.12	 	“Sponsored Research Agreement”	 	 	2	 
	 
	 	1.13	 	“Technology”	 	 	2	 
	 
	 	1.14	 	“Transfer Taxes”	 	 	2	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE II TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY	 	 	3	 
	 
	 	2.1	 	Transfer of Rights and License of Technology	 	 	3	 
	 
	 	2.2	 	Excluded Assets and Liabilities	 	 	3	 
	 
	 	2.3	 	Payment	 	 	3	 
	 
	 	2.4	 	Taxes	 	 	3	 
	 
	 	2.5	 	Assigned Rights	 	 	3	 
	 
	 	2.6	 	Unassignable Rights	 	 	3	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE III THE CLOSING	 	 	4	 
	 
	 	3.1	 	The Closing	 	 	4	 
	 
	 	3.2	 	Termination of License Agreement	 	 	4	 
	 
	 	3.3	 	Agreements Between Fluidigm and UABRF	 	 	5	 
	 
	 	3.4	 	Other Documents	 	 	5	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE IV REPRESENTATIONS AND WARRANTIES OF OCULUS	 	 	5	 
	 
	 	4.1	 	Organization	 	 	5	 
	 
	 	4.2	 	Authorization	 	 	5	 
	 
	 	4.3	 	No Conflicts; Consents	 	 	5	 
	 
	 	4.4	 	Title to Assigned Rights	 	 	6	 
	 
	 	4.5	 	No Assignment	 	 	6	 
	 
	 	4.6	 	Litigation and Claims	 	 	6	 
	 
	 	4.7	 	Distribution Agreement	 	 	6	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE V REPRESENTATIONS AND WARRANTIES OF FLUIDIGM	 	 	7	 
	 
	 	5.1	 	Organization	 	 	7	 
	 
	 	5.2	 	Authorization	 	 	7	 
	 
	 	5.3	 	No Conflicts; Consents	 	 	7	 
	 
	 	5.4	 	Litigation and Claims	 	 	8	 

i

 

TABLE OF CONTENTS
 (continued)

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 
	 	5.5	 	Securities Laws Exemptions	 	 	8	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE VI REPRESENTATIONS AND WARRANTIES OF UABRF	 	 	8	 
	 
	 	6.1	 	Authorization	 	 	8	 
	 
	 	6.2	 	No conflicts; Consents	 	 	8	 
	 
	 	6.3	 	Title to Technology	 	 	9	 
	 
	 	6.4	 	Litigation and Claims	 	 	9	 
	 
	 	6.5	 	Distribution Agreement	 	 	9	 
	 
	 	6.6	 	Investment Representations	 	 	10	 
	 
	 	6.7	 	Restrictions	 	 	10	 
	 
	 	6.8	 	Restrictive Legend	 	 	10	 
	 
	 	6.9	 	Notice of Proposed Transfers	 	 	11	 
	 
	 	6.10	 	Standoff Agreement	 	 	11	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE VII COVENANTS OF OCULUS	 	 	12	 
	 
	 	7.1	 	Conduct of Business	 	 	12	 
	 
	 	7.2	 	Access to Information	 	 	13	 
	 
	 	7.3	 	Regulatory Approvals	 	 	13	 
	 
	 	7.4	 	Satisfaction of Conditions Precedent	 	 	13	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE VIII COVENANTS OF UABRF	 	 	13	 
	 
	 	8.1	 	Conduct of Business	 	 	13	 
	 
	 	8.2	 	Access to Information	 	 	14	 
	 
	 	8.3	 	Regulatory Approvals	 	 	14	 
	 
	 	8.4	 	Satisfaction of Conditions Precedent	 	 	14	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE IX COVENANTS OF FLUIDIGM	 	 	14	 
	 
	 	9.1	 	Regulatory Approvals	 	 	14	 
	 
	 	9.2	 	Satisfaction of Conditions Precedent	 	 	15	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE X MUTUAL COVENANTS	 	 	15	 
	 
	 	10.1	 	Confidentiality	 	 	15	 
	 
	 	10.2	 	Publicity	 	 	15	 
	 
	 	10.3	 	Governmental Filings	 	 	15	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XI CONDITIONS TO CLOSING	 	 	15	 
	 
	 	11.1	 	Conditions to Each Party’s Obligations	 	 	15	 
	 
	 	11.2	 	Conditions to Obligations of  Oculus and UABRF	 	 	16	 
	 
	 	11.3	 	Conditions to Obligations of Fluidigm	 	 	16	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XII POST-CLOSING MATTERS	 	 	17	 
	 
	 	12.1	 	Additional Payments by Fluidigm	 	 	17	 
	 
	 	12.2	 	Settlement of Lawsuit	 	 	18	 

ii

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	ARTICLE XIII TERMINATION OF AGREEMENT	 	 	18	 
	 
	 	13.1	 	Termination by Fluidigm	 	 	18	 
	 
	 	13.2	 	Termination by UABRF	 	 	18	 
	 
	 	13.3	 	Mutual Consent	 	 	18	 
	 
	 	13.4	 	Effect of Termination	 	 	19	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XIV SURVIVAL OF REPRESENTATIONS AND WARRANTIES	 	 	19	 
	 
	 	14.1	 	Survival of Representations and Warranties	 	 	19	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE XV GENERAL	 	 	19	 
	 
	 	15.1	 	Governing Law	 	 	19	 
	 
	 	15.2	 	Assignment; Binding upon Successors and Assigns	 	 	19	 
	 
	 	15.3	 	Severability	 	 	19	 
	 
	 	15.4	 	Entire Agreement	 	 	20	 
	 
	 	15.5	 	Counterparts	 	 	20	 
	 
	 	15.6	 	Expenses	 	 	20	 
	 
	 	15.7	 	Other Remedies	 	 	20	 
	 
	 	15.8	 	Amendment	 	 	20	 
	 
	 	15.9	 	Waiver	 	 	20	 
	 
	 	15.10	 	Informal  Resolution	 	 	21	 
	 
	 	15.11	 	Mediation	 	 	21	 
	 
	 	15.12	 	Notices	 	 	21	 
	 
	 	15.13	 	Construction and Interpretation of Agreement	 	 	22	 
	 
	 	15.14	 	No Joint Venture	 	 	22	 
	 
	 	15.15	 	Absence of Third Party Beneficiary Rights	 	 	22	 
	 
	 	15.16	 	Further Assurances	 	 	23	 

iii

 

EXHIBITS AND SCHEDULES

	 	 	 
	Exhibit	 	Description
	A

	 	Amended and Restated Articles of Incorporation of Fluidigm
	B

	 	Form of New License Agreement
	C

	 	Form of Sponsored Research Agreement
	D

	 	Description of Technology
	 
	 	 
	Schedule

	 	Description
	4.6

	 	Pending Litigation

iv

 

MASTER CLOSING AGREEMENT

     THIS
MASTER CLOSING AGREEMENT is entered into as of March 7, 2003 by and among FLUIDIGM
CORPORATION, a California corporation (“Fluidigm”), OCULUS PHARMACEUTICALS, INC., a Delaware
corporation (“Oculus”), and THE UAB RESEARCH FOUNDATION (“UABRF”).

RECITALS

     A. Oculus and UABRF have entered into a license agreement dated September 21,
2001 (together with all amendments and modifications thereto, the “License Agreement”)
under which Oculus was granted an exclusive license to practice the intellectual property and
technology relating to nanovolume crystallization arrays described in Schedule A to the
License Agreement.

     B. The parties hereto have entered into a binding letter agreement dated
December 19, 2002 (the “Letter Agreement”) under which Oculus and UABRF have agreed to
terminate the License Agreement, UABRF has agreed to grant to Fluidigm an exclusive license
to practice the intellectual property and technology relating to nanovolume crystallization
arrays covered by the License Agreement, and Fluidigm and UABRF have agreed to enter into a
sponsored research agreement. In exchange for the rights to be acquired by Fluidigm as
contemplated by the Letter Agreement, Fluidigm has paid cash in the amount of [***]
pursuant to the Letter Agreement and has agreed to the payment of additional cash and
securities as specified in the Letter Agreement.

     C. The parties desire to enter into this Agreement to set out additional terms and
conditions related to the closing of the transactions, and the payments to be made by
Fluidigm, contemplated by the Letter Agreement.

     NOW, THEREFORE, in consideration of the representations, warranties and agreements herein
contained, the parties agree as follows:

ARTICLE I

DEFINITIONS

     As used in this Agreement, the following terms shall have the meanings set forth or
referenced below:

     1.1 “Affiliate” of any specified person shall mean any other person directly or
indirectly controlling or controlled by or under direct or indirect common control with such
specified person. For purposes of this definition, “control” when used with respect to any
specified person means the power to direct or cause the direction of the management and policies of
such person, directly or indirectly, whether through the ownership of voting securities, by
contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to
the foregoing.

-1-

 

     1.2 “Ancillary Documents” shall mean all documents or agreements required by this
Agreement to be executed or delivered by any party hereto.

     1.3 “Assigned Rights” shall mean any intellectual property rights owned by Oculus that
pertain in any way to the Technology, including without limitation any Inventions (as such term is
defined in Section 11 of the License Agreement) and any other patent rights and other intellectual
property rights therein owned by Oculus.

     1.4 “Cash Consideration” shall mean the sum of cash in the amount of [***] paid in
accordance with the Letter Agreement and the Closing Cash Consolidation.

     1.5 “Closing” shall mean the closing of the transactions contemplated by this
Agreement.

     1.6 “Closing Cash Consideration” shall mean cash in the amount of [***].

     1.7
“Closing Date” shall mean March 7, 2003, or such other date to which the parties
shall mutually agree in writing.

     1.8 “Encumbrances” shall mean restrictions on or conditions to transfer or assignment,
claims, liabilities, licenses, immunities from lawsuits to third parties, liens, pledges, mortgages
or security interests of any kind, whether accrued, absolute, contingent, or otherwise.

     1.9 “Fluidigm Series C Preferred Stock” shall mean the Series C Preferred Stock of
Fluidigm having the rights, preferences and privileges set forth in Fluidigm’s Articles of
Incorporation attached hereto as Exhibit A.

     1.10 “License Agreement” shall mean the license agreement between Oculus and
UABRF as described in Recital A.

     1.11 “New License Agreement” shall mean the license agreement between Fluidigm and
UABRF in the form of Exhibit B attached hereto.

     1.12 “Sponsored Research Agreement” shall mean the sponsored research agreement
between Fluidigm and UABRF in the form of Exhibit C attached hereto.

     1.13 “Technology” shall mean all intellectual property and other rights relating
to nanovolume crystallization arrays described in Exhibit D attached hereto.

     1.14
“Transfer Taxes” shall mean all sales taxes, use taxes, conveyance taxes,
transfer taxes, filing fees, recording fees, reporting fees and other similar duties, taxes and
fees, if any, imposed upon, or resulting from, the transfer of the Assigned Rights hereunder,
except federal, state or local income or similar taxes based upon or measured by revenue, income,
profit or gain from the transfer of the Assigned Rights or the operation of Oculus’ business prior
to the Closing or by any increase in the value of any of the Assigned Rights through the Closing
Date.

-2-

 

ARTICLE II

TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY

     2.1
Transfer of Rights and License of Technology. Oculus and UABRF have mutually
terminated the License Agreement as of January 30, 2003 and Oculus has surrendered all rights under
the License Agreement to UABRF. Subject to and upon the terms and conditions of this Agreement,
effective as of the Closing, Fluidigm and UABRF will enter into the New License Agreement. It is
the intent of the parties that all intellectual property rights subject to the License Agreement as
of November 27, 2002 shall be transferred and/or assigned to Fluidigm, and that all such rights
owned by UABRF shall be licensed to Fluidigm under the New License Agreement, subject to the
reservation by UABRF of certain rights as set forth in the License Agreement.

     2.2 Excluded Assets and Liabilities. Notwithstanding the provisions of Section 2.1,

(a) Fluidigm and Oculus expressly acknowledge and agree that Oculus shall not sell, transfer,
assign, convey or deliver to Fluidigm, and Fluidigm shall not purchase, acquire or accept from
Oculus, any right, title or interest of Oculus in or to any other property or assets of Oculus, and

(b) Fluidigm does not assume, and Oculus does not transfer or assign, any liabilities or
obligations, whether presently fixed and determined, contingent or otherwise, of Oculus.

     2.3 Payment. In
consideration of the execution of the New License Agreement and the
transfer of the rights thereunder, Fluidigm will deliver to UABRF the Closing Cash Consideration
and [ * * * ] shares of Fluidigm Series C
Preferred Stock valued at 2.58 per share, the price at
which Fluidigm sold and issued shares of its Series C Preferred Stock to other investors.

     2.4 Taxes. Fluidigm and Oculus shall each pay (or reimburse the other for) one-half of
all Transfer Taxes, whether imposed by law on Fluidigm and Oculus or otherwise.

     2.5 Assigned Rights. Oculus hereby sells, assigns and transfers to Fluidigm
all Assigned Rights, free and clear of all Encumbrances (except to the extent that the
settlement agreement pertaining to the Lawsuit (as such term is defined in Section 6.3) may
include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement).

     2.6 Unassignable Rights.

          (a) Notwithstanding any provision of this Agreement or any of the Ancillary Documents, but
subject to Section 11.3(c), to the extent that any of the Assigned Rights are not assignable or
otherwise transferable to Fluidigm, or if such assignment or transfer would constitute a breach
thereof or a violation of any applicable law, then neither this Agreement nor such Ancillary
Documents shall constitute an assignment or transfer (or an attempted assignment or transfer)
thereof until such consent, approval or waiver of such party or parties has been duly obtained.

          (b) If any consent required to transfer the Assigned Rights to Fluidigm has not been obtained
as of the Closing Date and Fluidigm nevertheless determines to proceed with the

-3-

 

Closing, Oculus and UABRF shall, at their own expense, continue to cooperate with Fluidigm and use
commercially reasonable efforts to obtain such consent after the Closing.

          (c) If any Assigned Right is not transferred to Fluidigm at the Closing pursuant to this
Agreement, Oculus and Fluidigm shall cooperate with each other in any reasonable arrangement
designed to provide for Fluidigm all of the benefits of such Assigned Rights. At Fluidigm’s
request, Oculus shall take all reasonable actions requested by Fluidigm to enforce for the benefit
of Fluidigm any and all rights of Oculus with respect to any such Assigned Right that is not
otherwise transferred pursuant to the provisions of this Agreement. Oculus agrees to hold in trust
for, and remit promptly to, Fluidigm all future collections or payments received by Oculus in
respect of all such Assigned Rights (net of all costs and expenses incurred by Oculus in respect
thereto); provided, however, that nothing herein shall create or provide any rights or
benefits in or to third parties.

          (d) If any intellectual property rights that are described in the New License Agreement cannot
be licensed to Fluidigm by UABRF under the New License Agreement without the consent of any third
party or without resulting in a breach or default of any agreement affecting such rights, UABRF
covenants and agrees that it shall not sue or otherwise take any legal action to restrict or
prevent Fluidigm and Fluidigm’s permitted assignees and sublicensees from practicing such
intellectual property rights as purported to be granted under the terms of the New License
Agreement.

          (e) If, subsequent to the Closing, a claim brought by any party challenging any of the
transactions contemplated hereby results in any ruling or order which has the result of frustrating
in a material way the transfer of any of the Assigned Rights hereunder to Fluidigm or the grant of
rights to Fluidigm under the New License Agreement or Fluidigm’s use thereof as provided herein,
Oculus and UABRF shall cooperate with Fluidigm in any reasonable arrangement designed to give
Fluidigm, as nearly as practicable, the same economic benefits as if such transfer or license, as
the case may be, had been consummated in accordance with the provisions hereof.

          (f) Nothing in this Section 2.6 shall be deemed to modify in any respect any of the
representations or warranties of Oculus and UABRF set forth herein or the conditions to Fluidigm’s
obligations contained in this Agreement, be deemed a waiver by Fluidigm of its right to have
received on or before the Closing Date an effective assignment of all of the Assigned Rights or be
deemed to constitute an agreement to exclude any assets from the Assigned Rights.

ARTICLE III

THE CLOSING

     3.1 The Closing. The Closing shall take place at the offices of Gray Cary Ware &
Freidenrich llp, 400 Hamilton Avenue, Palo Alto, California, at 11:00 a.m., Pacific Time,
on the Closing Date, or at such other time and place as Oculus, Fluidigm and UABRF may agree.

     3.2 Termination of License Agreement. On or before the Closing, Oculus and UABRF
shall deliver to Fluidigm an agreement and acknowledgment that the License

-4-

 

Agreement has been terminated and such other agreements and instruments as may be necessary or
appropriate to evidence the return by Oculus to UABRF of all rights under the License Agreement.

     3.3
Agreements Between Fluidigm and UABRF. At the Closing, Fluidigm and UABRF shall execute and deliver the New License Agreement and the
Sponsored Research Agreement.

     3.4 Other Documents. Each party shall deliver to the other at the Closing such other
documents, certificates, schedules, agreements and instruments required by this Agreement to
be delivered at such time.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF OCULUS 

     Oculus hereby represents and warrants to Fluidigm as follows:

     4.1 Organization. Oculus is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Delaware and has all requisite corporate power to
own, lease and operate its properties and to conduct its business as it is currently being
conducted. Oculus is duly qualified or licensed to do business as a foreign corporation in
each jurisdiction in which the failure to be so qualified or licensed would have a material adverse
effect on Oculus.

     4.2  Authorization. This Agreement and all of the Ancillary Documents to which
Oculus is or will be a party have been, or upon their execution and delivery hereunder will have
been, duly and validly executed and delivered by Oculus and constitute, or will constitute, valid
and binding agreements of Oculus, enforceable against Oculus in accordance with their respective
terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors’ rights generally or by principles of public policy
or general equitable principles or the exercise of judicial discretion in accordance with such
principles. Oculus has the requisite corporate power and authority to execute and deliver this
Agreement and the Ancillary Documents to which Oculus is or will be a party and, at the time of the
Closing, will have the requisite corporate power and authority to carry out the transactions
contemplated by this Agreement and the Ancillary Documents. The execution, delivery and performance
by Oculus of this Agreement and the Ancillary Documents have been duly and validly approved and
authorized by the Board of Directors and shareholders of Oculus.

     4.3 No Conflicts; Consents. The execution and delivery by Oculus of this Agreement
and the Ancillary Documents to which Oculus is or will be a party do not, and the consummation
of the transactions contemplated hereby and thereby and compliance by Oculus with the
provisions hereof and thereof will not, contravene, conflict with, result in a breach of,
constitute a default (with or without notice or lapse of time, or both) under or violation of, or result
in the creation of any Encumbrance pursuant to, (i) any provision of the Certificate of Incorporation
or Bylaws of Oculus, (ii) any judgment, order, decree, rule, law or regulation of any court or

-5-

 

governmental authority, foreign or domestic, applicable to Oculus or to any of the Assigned Rights,
except where any such contravention, conflict, breach or default could not reasonably be expected
to have a material adverse effect on Fluidigm’s ownership of the Assigned Rights, or (iii) any
provision of any material agreement, instrument or understanding to which Oculus is a party or by
which Oculus is bound or any of the Assigned Rights are affected, except where any such
contravention, conflict, breach or default could not reasonably be expected to have a material
adverse effect on Fluidigm’s ownership of the Assigned Rights, nor will such actions give to any
other person or entity any interests or rights of any kind, including rights of termination,
acceleration or cancellation, in or with respect to any of the Assigned Rights, or result in the
creation of any Encumbrance on any of the Assigned Rights. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of Oculus to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.

     4.4 Title to Assigned Rights. Oculus has good and marketable title to all of the
Assigned Rights. All of the Assigned Rights are free and clear of any Encumbrances (except to the
extent that the settlement agreement pertaining to the Lawsuit (as such term is defined in Section
6.3) may include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement). At the Closing, Oculus will sell, convey, assign, transfer and deliver to Fluidigm
good, valid and marketable title and all right and interest in and to all of the Assigned Rights,
free and clear of any Encumbrances.

     4.5 No Assignment. Oculus has not sublicensed or otherwise transferred any material
rights under the License Agreement to any third party. As of
December 19, 2002, the License
Agreement was in full force and effect in accordance with its terms. Prior to the termination of
the License Agreement, no provisions of the License Agreement had been waived in any
material respect. Exhibit D lists all of the patent filings subject to the License
Agreement. To the knowledge of Oculus, UABRF is the owner of the patent rights within the
technology and inventions subject to the License Agreement and has not granted a license to such
technology and inventions to any person or entity other than Oculus.

     4.6 Litigation and Claims. Except as set forth on Schedule 4.6 attached hereto, there
are no claims, actions, suits, proceedings arbitrations or investigations in progress or pending
(or, to the knowledge of Oculus, threatened) before any court, tribunal or governmental agency
against Oculus that relate to any of the Assigned Rights. Oculus is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial or
arbitration proceeding with any governmental authority) with respect to any of the Assigned Rights.

     4.7 Distribution Agreement. Oculus has entered into a mutually acceptable
agreement with UABRF regarding the distribution of any and all consideration to be paid by
Fluidigm in connection with the transactions contemplated by this Agreement.

-6-

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF FLUIDIGM 

     Fluidigm hereby represents and warrants to Oculus and UABRF as follows:

     5.1 Organization. Fluidigm is a corporation duly organized, validly existing and
in good standing under the laws of the State of California and has all requisite corporate power to
own, lease and operate its properties, to conduct its business as it is currently being conducted.
Fluidigm is duly qualified or licensed to do business as a foreign corporation in each jurisdiction
in which the failure to be so qualified or licensed would have a material adverse effect on
Fluidigm.

     5.2
Authorization. This Agreement and all of the Ancillary Documents to which Fluidigm
is or will be a party have been, or upon their execution and delivery hereunder will have been,
duly and validly executed by Fluidigm and constitute, or will constitute, valid and binding
agreements of Fluidigm, enforceable against Fluidigm in accordance with their respective terms,
except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors’ rights generally or by principles of public policy or general
equitable principles or the exercise of judicial discretion in accordance with such principles.
Fluidigm has the requisite corporate power and authority to execute and deliver this Agreement and
the Ancillary Documents to which Fluidigm is or will be a party and, at the time of the Closing,
will have the requisite corporate power and authority to sell, issue and deliver the Securities
pursuant to this Agreement and to carry out the other transactions contemplated by this Agreement
and the Ancillary Documents. The execution, delivery and performance by Fluidigm of this Agreement
and the Ancillary Documents have been duly and validly approved and authorized by Fluidigm’s Board
of Directors and by all requisite action of Fluidigm’s stockholders.

     5.3
No Conflicts; Consents. The execution and delivery by Fluidigm of this Agreement
and the Ancillary Documents to which Fluidigm is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by Fluidigm with the provisions
hereof and thereof will not, contravene, conflict with, result in a breach of, constitute a default
(with or without notice or lapse of time, or both) under or violation of, or result in the creation
of any Encumbrance pursuant to, (i) any provision of the Articles of Incorporation or Bylaws of
Fluidigm, (ii) any judgment, order, decree, rule, law or regulation of any court or governmental
authority, foreign or domestic, applicable to Fluidigm except where such any such contravention,
conflict, breach or default could not reasonably be expected to have a material adverse effect on
the consummation of the transactions contemplated hereby, or
(iii) any provision of any agreement, instrument or understanding to which Fluidigm is a party or
by which Fluidigm is bound, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on the consummation of the
transactions contemplated hereby. No consent, approval, order or authorization of, or registration,
declaration or filing with, any third party or any governmental authority is required to be
obtained on the part of Fluidigm to permit the consummation of the transactions contemplated by
this Agreement or the Ancillary Documents.

-7-

 

     5.4 Litigation and Claims. There are no claims, actions, suits, proceedings,
arbitrations or investigations in progress or pending (or, to Fluidigm’s knowledge, threatened,
other than potential claims relating to the Interfering Patent (as such term is defined in Section
12.1(a) below), including, but not limited to, a possible interference) before any court, tribunal
or governmental agency, against or relating to Fluidigm, which, if determined adversely to
Fluidigm, would be likely to have a material adverse effect upon Fluidigm’s financial condition or
materially impair its ability to carry out and perform its obligations hereunder.

     5.5 Securities Laws Exemptions. Based in part on the representations of UABRF
contained in Section 6.5, the issuance of the Securities pursuant to the terms of this Agreement
will be exempt from the registration requirements of the Securities Act and the regulations
thereunder, and the registration, permit or qualification requirements of any applicable state
securities laws.

ARTICLE VI

REPRESENTATIONS AND WARRANTIES OF UABRF

     To the best knowledge of the UABRF Director and Dr. Larry DeLucas, UABRF hereby represents to
Fluidigm as follows:

     6.1 Authorization. This Agreement and the Ancillary Documents to which UABRF is
or will be a party have been, or upon their execution and delivery hereunder will have been, duly
and validly executed and delivered by UABRF and constitute, or will constitute, valid and binding
agreements of UABRF, enforceable against UABRF in accordance with their respective terms, except as
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors’ rights generally or by principles of public policy or general equitable
principles or the exercise of judicial discretion in accordance with such principles. UABRF has
full power and authority to execute and deliver this Agreement and the Ancillary Documents to which
UABRF is or will be a party and, at the time of the Closing, will have all requisite power and
authority to carry out the transactions contemplated by this Agreement and the Ancillary Documents.
All university, foundation and other internal approvals necessary for UABRF to consummate the
transactions contemplated by this Agreement and the Ancillary Documents to which UABRF is or will
be a party have been obtained.

     6.2 No Conflicts; Consents. The execution and delivery by UABRF of this Agreement
and the Ancillary Documents to which UABRF is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by UABRF with the provisions hereof
and thereof will not, contravene, conflict with, result in a breach of, constitute a default (with
or without notice or lapse of time, or both) under or violation of, or result in the creation of
any Encumbrance pursuant to, (i) any provision of the charter documents of UABRF, (ii) any
judgment, order, decree, rule, law or regulation of any court or governmental authority, foreign or
domestic, applicable to UABRF or to the Technology, except where any such contravention, conflict,
breach or default could not reasonably be expected to have a material adverse effect on Fluidigm’s
rights under the New License Agreement or the consummation of the transactions contemplated hereby,
or (iii) any provision of any agreement, instrument or understanding to which UABRF is a party or
by which UABRF is bound or any of

-8-

 

the Technology is affected, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on Fluidigm’s rights under the
New License Agreement or the consummation of the transactions contemplated hereby, nor will such
actions give to any other person or entity any interests or rights of any kind, including rights
of termination, acceleration or cancellation, in or with respect to any of the Technology, or
result in the creation of any Encumbrance on any of the Technology. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of the UABRF to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.

     6.3 Title to Technology. UABRF is the sole owner of the technology, inventions and
patent rights in the Technology and subject to the License Agreement and has not granted a
license to such technology, inventions and patent rights to any person or entity other than
Oculus. The License Agreement has been mutually terminated by UABRF and Oculus and
neither Oculus nor any other party has any rights thereunder. UABRF has the right to grant an
exclusive license to the technology, inventions, patent rights and other rights under the New
License Agreement to Fluidigm, free and clear of any Encumbrances of any nature whatsoever,
subject to those liens, encumbrances or restrictions which may arise as a result of the
settlement of the litigation between Oculus and Syrrx, Inc. (“Syrrx”) described in Schedule 4.6
(the “Lawsuit”), provided that Syrrx shall have no rights that may be exercised after the
Closing to practice the technology, inventions, patent rights and
other rights subject to the New License Agreement, and the potential infringement by Diversified Scientific, Inc. of the Licensed IP
Rights (as such term is defined in the New License Agreement) described in Section 2.2.3 of
the New License Agreement. Exhibit D lists all of the patent filings subject to the
License Agreement. UABRF is not aware of any third-party challenges to the ownership, validity or
entitlement to priority date of any of the patent filings subject to the License Agreement or
the New License Agreement, except for the Lawsuit between Oculus and Syrrx and the settlement
agreement related to said Lawsuit provided to Fluidigm pursuant to Section 7.2 of this
Agreement.

     6.4 Litigation and Claims. Except as set forth on Schedule 4.6 attached hereto, there
are no claims, actions, suits, proceedings, arbitrations or investigations in progress or
pending (or, to the knowledge of UABRF, threatened) before any court, tribunal or governmental agency

against UABRF that relate to any of the Technology. UABRF is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial
or arbitration proceeding with any governmental authority) with respect to any of the Technology,
except to the extent that UABRF may be deemed to be a party thereto as a result of UABRF’s
status as a shareholder of Oculus and having a member on the Board of Directors of Oculus as
well as the status of Dr. Larry DeLucas as a member of the Board of Directors of Oculus and a
shareholder of Oculus.

     6.5 Distribution Agreement. UABRF has entered into a mutually acceptable
agreement with Oculus regarding the distribution of any and all consideration to be paid
by Fluidigm in connection with the transactions contemplated by this Agreement.

-9-

 

     6.6 Investment Representations

          (a) UABRF is acquiring the shares of Fluidigm capital stock to be issued
hereunder (the “Securities”) for investment and not with the view to the public resale
or distribution thereof, and UABRF has no present intention of selling, granting any
participation in, or otherwise distributing the Securities, other than in accordance with the terms of a
Termination Agreement dated as of ____, 2003 between UABRF and Oculus.
UABRF understands that the Securities have not been registered under the Securities Act by reason
of a specific exemption thereunder, which depends upon, among other things, the bona fide nature of
UABRF’s investment intent as expressed herein.

          (b) UABRF acknowledges that the Securities must be held indefinitely unless they are
subsequently registered under the Securities Act or Fluidigm receives an opinion of counsel
satisfactory to Fluidigm that such registration is not required. UABRF is aware of the provisions
of Rule 144 promulgated under the Securities Act which permit limited resale of stock purchased in
a private placement subject to the satisfaction of certain conditions.

          (c) UABRF understands that no public market now exists for the Securities and that there can
be no assurance that a public market will ever exist for the Securities.

          (d) UABRF is an “accredited investor” as defined in the Securities Act, and has such knowledge
and experience in financial and business matters that it is capable of evaluating the merits and
risks of the investment in the Securities.

          (e) UABRF has been given the opportunity to obtain any information or documents related to,
and ask questions and receive answers about Fluidigm and its business, prospects and risks which
UABRF deems necessary, to evaluate the merits and risks related to UABRF’s investment in the
Securities and to verify the information UABRF received.

          (f) UABRF’s financial condition is such that it can afford to bear the economic risk of
holding the Securities for an indefinite period of time, and it has adequate means of providing for
its current needs and contingencies and to suffer a complete loss of its investment in such
Securities.

     6.7 Restrictions. No Securities shall be sold, assigned, transferred or pledged except
upon the conditions specified in this Agreement. UABRF will cause any proposed purchaser, assignee,
transferee or pledgee of the Securities to agree in writing to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement.

     6.8 Restrictive Legend. Each certificate representing the Securities shall (unless
otherwise permitted by the provisions of Section 6.9 below) be stamped or otherwise imprinted with
a legend in the following form (in addition to any legend required under applicable state
securities laws):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED
FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”). SUCH

-10-

 

SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE
OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF
COUNSEL (WHICH MAY BE COUNSEL FOR THE COMPANY) OR OTHER EVIDENCE
REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS
EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF THE SECURITIES ACT.”

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A MARKET
STAND-OFF AGREEMENT IN THE EVENT OF A PUBLIC OFFERING, A COPY OF WHICH
IS ON FILE WITH THE SECRETARY OF THE COMPANY.”

     UABRF consents to Fluidigm making a notation on its records and giving instructions to any
transfer agent of the Securities in order to implement the restrictions on transfer established in
Sections 6.7 through 6.10 of this Agreement.

     6.9 Notice of Proposed Transfers. UABRF and any transferee of any certificate
representing the Securities, by acceptance thereof, agrees to comply in all respects with the
restrictions on transfer contained in Sections 6.7 through 6.10 of this Agreement. Prior to any
proposed sale, assignment, transfer or pledge of any Securities (other than any transfer not
involving a change in beneficial ownership), unless there is in effect a registration statement
under the Securities Act covering the proposed transfer, the holder thereof shall give written
notice to Fluidigm of such holder’s intention to effect such transfer, sale, assignment or pledge.
Each such notice shall describe the manner and circumstances of the
proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder’s expense by
either (i) a written opinion of legal counsel who shall, and whose legal opinion shall be,
reasonably satisfactory to Fluidigm, addressed to Fluidigm, to the effect that the proposed
transfer of the Securities may be effected without registration under the Securities Act, or (ii) a
“no action” letter from the Securities and Exchange Commission (the “Commission”) to the effect
that the transfer of such Securities without registration will not result in a recommendation by
the staff of the Commission that action be taken with respect thereto, or (iii) any other evidence
reasonably satisfactory to counsel to Fluidigm, whereupon the holder of such Securities shall be
entitled to transfer such Securities in accordance with the terms of the notice delivered by the
holder to Fluidigm; provided, however, that no such legal opinion, “no action” letter or other
evidence shall be required with respect to a transfer to an affiliate of the holder. Each
certificate evidencing the Securities transferred as above provided shall bear, except if such
transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth in Section 6.8
above, except that such certificate shall not bear such restrictive legend if, in the opinion of
counsel for such holder and Fluidigm, such legend is not required in order to establish compliance
with any provisions of the Securities Act or this Agreement.

     6.10 Standoff Agreement. UABRF agrees in connection with Fluidigm’s initial sale of
securities pursuant to an effective registration statement, upon notice by Fluidigm or the
underwriters managing such offering, not to sell, make any short sale of, loan, pledge (or

-11-

 

otherwise encumber or hypothecate), grant any option for the purchase of, or otherwise directly or
indirectly dispose of any Securities (other than those included in the registration) without the
prior written consent of Fluidigm and such managing underwriters for such period of time as
Fluidigm’s Board of Directors establishes pursuant to its good faith negotiations with such
managing underwriters; provided, however that:

               (i) such agreement shall not exceed one hundred eighty (180) days;

               (ii) such agreement shall not apply to transfers to an affiliate, provided that such
affiliate agrees to be bound by the terms of such agreement, to the same extent as if such
transferee were the original party thereunder;

               (iii) UABRF shall not be subject to such agreement unless (A) all executive officers and
directors of Fluidigm, (B) all shareholders of Fluidigm holding more than 1% of Fluidigm’s
outstanding capital stock and (C) all holders of registration rights, are subject to or obligated
to enter into similar agreements; and

               (iv) if and when any person identified in clause (iii) is released, in whole or in part,
from such agreement (whether or not such release is contemplated at the time of the offering) or if
any such agreement is terminated, UABRF shall be concurrently released on a pro rata basis based on
the number of Securities held by such person and UABRF.

          (b) UABRF agrees that prior to the initial public offering it will not transfer
securities of Fluidigm unless each transferee agrees in writing to be bound by all of the
provisions of this Section 6.10, provided that this Section 6.10 shall not apply to transfers
pursuant to a registration statement.

     UABRF hereby consents to the placement of stop transfer orders with Fluidigm’s transfer agent
in order to enforce the foregoing provision and agrees to execute a market standoff agreement with
said underwriters in customary form consistent with the provisions of this Section 6.10.

ARTICLE VII

COVENANTS OF OCULUS

     7.1 Conduct of Business. During the period from the date of this Agreement to the
Closing, Oculus will conduct its business in the ordinary course consistent with past
practices. During the period from the date of this Agreement to the Closing, Oculus will not
without the prior written consent of Fluidigm:

          (a) encumber or permit to be encumbered any of the Technology or Assigned Rights;

          (b) dispose of any of the Technology or Assigned Rights;

          (c) waive or release any right or claim relating to any Technology or Assigned Rights; or

-12-

 

          (d) agree to do any of the things described in the preceding clauses of this Section 7.1.

Fluidigm agrees that the foregoing restrictions will not prevent Oculus from entering into a
settlement agreement with Syrrx to settle the Lawsuit, provided that such settlement does not
involve the sale, transfer or assignment of the Technology or the Assigned Rights, or any rights in
any of the foregoing, or result in the creation of any Encumbrance on the Technology, the Assigned
Rights, or any rights in any of the foregoing.

     7.2 Access to Information. Until the earlier of the termination of this Agreement or
the Closing, Oculus will allow Fluidigm and its agents reasonable access upon reasonable notice and
during normal working hours to its files, books, records, and offices relating to the Technology
and Assigned Rights, except where prohibited by contract or protected by privilege. In furtherance
of the above, Fluidigm and its counsel and advisors shall have reasonable access during normal
business hours to pertinent contracts of Oculus, including an unsigned final version of the
settlement agreement between Oculus and Syrrx related to the Lawsuit, and drafts of such settlement
agreement (to the extent it is permissible under applicable confidentiality terms and with the
understanding that Oculus may be required to obtain the return or destruction by Fluidigm of the
final version and drafts of such settlement agreement prior to its execution), as well as all
scientific notebooks, invention records and other documents related to the conception and reduction
to practice and prosecution of the patent filings listed on
Exhibit D, including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations and
research related to the Technology, the License Agreement and the New License Agreement.

     7.3 Regulatory Approvals. Prior to the Closing, Oculus will execute and file, or join
in the execution and filing of, any application or other document that may be reasonably necessary
in order to obtain the authorization, approval or consent of any governmental entity that may be
required in connection with the consummation of the transactions contemplated by this Agreement.
Oculus will use commercially reasonable efforts to obtain all such authorizations, approvals and
consents.

     7.4
Satisfaction of Conditions Precedent. Oculus will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transactions contemplated hereby.

ARTICLE VIII

COVENANTS OF UABRF

     8.1 Conduct of Business. During the period from the date of this Agreement to
the Closing, UABRF will not without the prior written consent of Fluidigm:

          (a) encumber or permit to be encumbered any of the Technology;

-13-

 

          (b) dispose
of any of the Technology;

          (c) waive or release any right or claim relating to any Technology; or

          (d) agree to do any of the things described in the preceding clauses of this
Section 8.1.

Fluidigm agrees that the foregoing restrictions will not prevent UABRF from consenting to a
settlement agreement between Oculus and Syrrx to settle the Lawsuit, provided that such
settlement does not involve the sale, transfer or assignment of the Technology or the
Assigned Rights, or any rights in any of the foregoing, or result in the creation of any
Encumbrance on the Technology, the Assigned Rights, or any rights in any of the foregoing.

     8.2 Access to Information. Until the earlier of the termination of this
Agreement or the Closing, UABRF will allow Fluidigm and its agents reasonable access upon
reasonable notice and during normal working hours to its files, books, records, and offices
relating to the Technology and Assigned Rights, except where prohibited by contract or
protected by privilege. In furtherance of the above, Fluidigm and its counsel and advisors
shall have reasonable access during normal business hours to pertinent scientific notebooks,
invention records and other documents related to the conception and reduction to practice
and prosecution of the patent filings listed on Exhibit D, including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations
and research related to the Technology, the License Agreement and the New License Agreement.

     8.3 Regulatory Approvals. Prior to the Closing, UABRF will execute and file, or
join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any governmental entity
that may be required in connection with the consummation of the transactions contemplated by
this Agreement. UABRF will use commercially reasonable efforts to obtain all such
authorizations, approvals and consents.

     8.4 Satisfaction of Conditions Precedent. UABRF will use commercially
reasonable efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing
hereunder, and to cause the transactions contemplated hereby to be consummated, and, without
limiting the generality of the foregoing, to obtain all consents and authorizations of third parties
and to make all filings with, and give all notices to, third parties which may be necessary or
reasonably required on its part in order to effect the transactions contemplated hereby.

ARTICLE IX

COVENANTS OF FLUIDIGM

     9.1 Regulatory Approvals. Prior to the Closing, Fluidigm will execute and
file, or join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any
governmental entity that may be required in connection with the consummation of the
transactions contemplated by this Agreement. Fluidigm will use its commercially reasonable
efforts to obtain all such authorizations, approvals and consents.

-14-

 

     9.2 Satisfaction of Conditions Precedent. Fluidigm will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transaction contemplated hereby.

ARTICLE X

MUTUAL COVENANTS

     10.1 Confidentiality. The parties acknowledge that the Confidential Disclosure
Agreement dated as of October 8, 2002 between Fluidigm and Oculus and the Confidential Disclosure
Agreement dated December 19, 2002 between Fluidigm, Oculus and UABRF are binding upon the parties
hereto and in full force and effect, except to the extent that the provisions hereof supersede
provisions to similar effect contained in the Confidential Disclosure Agreements. The terms of the
Confidential Disclosure Agreements (exclusive of such superseded provisions) are incorporated in
this Agreement by this reference.

     10.2 Publicity. Except as may otherwise be required by law, none of the parties hereto
shall make or cause to be made any public announcements in respect of this Agreement or the
transactions contemplated herein or otherwise communicate with any news media without the prior
written consent of the other party, provided, however, that following the Closing Fluidigm may
issue a press release to announce the closing of the transactions contemplated hereby and the
execution and delivery of the New License Agreement and Sponsored Research Agreement with UABRF
provided that such press release shall not be issued prior to the execution by Syrrx
of a settlement agreement with Oculus to settle the litigation described in Schedule 4.6 but in any
event the press release may be issued no later than 30 days from the execution date of the New
License Agreement. Except for the press release issued by Fluidigm, none of the parties hereto will
make any public disclosure prior to the Closing or with respect to the Closing unless all parties
agree on the text and timing of such public disclosure, except as required by law. Nothing
contained in this Section shall prevent any party at any time from furnishing any information
pursuant to the requirements of any governmental entity; provided, however, that
if such party is required to furnish such information, it will provide a copy to the other parties.

     10.3 Governmental Filings. As promptly as practicable after the execution of this
Agreement, each party shall make any and all governmental filings required with respect to the
transactions contemplated in this Agreement and the Ancillary Documents.

ARTICLE XI

CONDITIONS TO CLOSING

     11.1 Conditions to Each Party’s Obligations. The respective obligations of each party
to effect the transactions to be performed by such party at the Closing are subject to the
satisfaction at or prior to the Closing of the following conditions any of which may be waived in
writing by each party:

-15-

 

          (a) No order shall have been entered, and not vacated, by a court or administrative agency
of competent jurisdiction, in any action or proceeding which enjoins, restrains or prohibits the
sale of the Assigned Rights, the grant of rights under the New License Agreement or the
consummation of any other transaction contemplated hereby.

          (b) All permits, authorizations, approvals and orders required to be obtained under all
applicable statutes, codes, ordinances, rules and regulations in connection with the transactions
contemplated hereby shall have been obtained and shall be in full force and effect at the Closing
Date.

          (c) There shall be no litigation pending or threatened by any regulatory body or private
party in which (i) an injunction is or may be sought against the transactions contemplated hereby,
or (ii) relief is or may be sought against any party hereto as a result of this Agreement and in
which, in the good faith judgment of the Board of Directors of either Fluidigm, Oculus or UABRF
(relying on the advice of their respective legal counsel), such regulatory body or private party
has the probability of prevailing and such relief would have a material adverse affect upon such
party.

     11.2 Conditions to Obligations of Oculus and UABRF. The obligations of Oculus and UABRF
to effect the transactions to be performed by Oculus and UABRF at the Closing are subject to the
satisfaction at or prior to the Closing of the following additional conditions any of which may be
waived in writing by Oculus and UABRF:

          (a) All of the representations and warranties of Fluidigm set forth in Article V hereof
shall be true in all material respects on and as of the Closing Date with the same force and effect
as if they had been made at the Closing, except for changes contemplated by this Agreement.

          (b) All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Fluidigm at or prior to the Closing shall have been duly complied with and performed
in all material respects.

     11.3 Conditions to Obligations of Fluidigm. The obligations of Fluidigm to effect the
transactions to be performed by it at the Closing are subject to the satisfaction at or prior to
the Closing of the following additional conditions any of which may be waived in writing by
Fluidigm:

          (a) All of the representations and warranties of Oculus and UABRF set forth in Articles IV
and VI hereof shall be true in all material respects on and as of the Closing Date with the same
force and effect as if they had been made at the Closing, except for changes contemplated by this
Agreement.

          (b) All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Oculus and UABRF at or prior to the Closing shall have been duly complied with and
performed in all material respects.

          (c) All required consents from third parties required to allow the consummation of the sale
of the Assigned Rights, the grant of rights under the New License

-16-

 

Agreement and the other transactions contemplated hereby shall have been obtained and delivered to
Fluidigm.

          (d) Fluidigm shall have received an opinion from the attorney(s) prosecuting the patent
filings listed on Exhibit D, in form and substance reasonably acceptable to Fluidigm, as to
the following matters: (i) assignments of the inventions covered by the patent filings to UABRF
have been properly filed with the United States Patent and Trademark Office (“USPTO”), (ii) UABRF
is named as the sole owner of the inventions covered by the patent filings listed on Exhibit
D, (iii) a declaration of interference was timely requested with at least one of the pending
U.S. patent applications listed on Exhibit D and U.S. Patent No. 6,296,673 with the USPTO
in accordance with U.S.C. Section 135, (iv) none of the patents listed on Exhibit D have
been held to be permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and none of the patents listed on Exhibit D have been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise, and (v) the patent applications listed on
Exhibit D were filed in good faith and have not been abandoned or finally disallowed
without the possibility of appeal or refiling of such application.

ARTICLE XII

POST-CLOSING MATTERS

     12.1 Additional Payments by Fluidigm. In addition to the consideration delivered by
Fluidigm at the Closing, Fluidigm will pay the following amounts to UABRF upon the achievement of
the following milestones:

          (a)
Milestone 1. Milestone 1 shall be satisfied [***]. Within
[***] days after [***], Fluidigm will issue shares of its stock having a
value of [***] (based on the fair value of the stock at the time Milestone 1 is achieved),
subject to compliance with applicable securities laws.

          (b)
Milestone 2. Milestone 2 shall be satisfied [***].
Within [***] days after [***], Fluidigm will issue shares of its stock having a value of [***]
(based on the fair value at the time Milestone 2 is achieved), subject to compliance with
applicable securities laws. In addition, (i) [***]

-17-

 

[***]

          (c) Stock to
be Issued. If Fluidigm is a private company at the time a milestone is
achieved, upon achievement of a milestone Fluidigm will issue shares of the series of Fluidigm
Preferred Stock that was issued in Fluidigm’s most recent financing and the shares will be valued
at the price at which the shares were sold in such financing. If Fluidigm is a public company at
the time a milestone is achieved, upon achievement of a milestone Fluidigm will issue shares of
Fluidigm Common Stock and the shares will be valued at the average closing price of Fluidigm’s
Common Stock over the five trading days preceding the achievement of the milestone.

     12.2
Settlement of Lawsuit. If the Lawsuit has not been settled or dismissed as of the
Closing Date:

          (a) Oculus agrees that Fluidigm and its counsel and advisors shall have reasonable access
during normal business hours to the final version of the settlement agreement between Oculus and
Syrrx related to the Lawsuit, and drafts of such settlement agreement (to the extent permissible
under applicable confidentiality terms), in the manner contemplated by Section 7.2 of this
Agreement, until the Lawsuit is settled or dismissed.

          (b) Oculus and UABRF agree that if a settlement agreement related to the Lawsuit is entered
into after the Closing Date, the settlement will not involve the sale, transfer or assignment of
the Technology or the Assigned Rights, or any rights in any of the foregoing, or result in the
creation of any Encumbrance on the Technology, the Assigned Rights, or any rights in any of the
foregoing.

ARTICLE XIII

TERMINATION OF AGREEMENT

     13.1 Termination by Fluidigm. This Agreement may be terminated at any time before the
Closing by action of the Board of Directors of Fluidigm upon written notice to Oculus and UABRF,
specifying the basis for such termination, if (i) Oculus or UABRF shall have breached in any
material respect any of their covenants or agreements contained in this Agreement, or (ii) any
representation or warranty of Oculus or UABRF contained in this Agreement shall have been
materially inaccurate.

     13.2 Termination by UABRF. This Agreement may be terminated at any time before the
Closing by action of the Board of Directors or other governing body of UABRF upon written notice to
Fluidigm, specifying the basis for such termination, if (i) Fluidigm shall have breached in any
material respect any of its covenants or agreements contained in this Agreement, or (ii) any
representation or warranty of Fluidigm contained in this Agreement shall have been materially
inaccurate.

     13.3 Mutual Consent. This Agreement may be terminated at any time before the Closing,
by the mutual written consent of Fluidigm, Oculus and UABRF.

-18-

 

     13.4
Effect of Termination. Upon any termination of this Agreement, all parties hereto
shall be relieved of all further obligations under this Agreement, except for the provisions of
Section 2.5 regarding the assignment by Oculus to Fluidigm of Assigned Rights, together with all
patent rights and all other intellectual property rights therein, Section 15.6 regarding the
payment of certain expenses and Section 10.1 regarding the continuing obligations of the parties
under the Confidential Disclosure Agreements.

ARTICLE XIV

SURVIVAL OF REPRESENTATIONS AND WARRANTIES

     14.1 Survival of Representations and Warranties. The representations and warranties set forth
in this Agreement shall survive the Closing for a period equal to the greater of 12 months after
the Closing Date or the date on which both Milestones specified in Section 12.1 have been achieved.
After the expiration of such period, such representations and warranties shall expire and be of no
further force and effect.

ARTICLE XV

GENERAL

     15.1
Governing Law. It is the intention of the parties hereto that the internal laws of
the State of California (irrespective of its choice of law principles) shall govern the validity of
this Agreement, the construction of its terms, and the interpretation and enforcement of the rights
and duties of the parties hereto; provided, however, that any disputes involving UABRF shall be
governed by the internal laws of the State of Alabama (irrespective of its choice of law principles
and any disputes involving UABRF shall be resolved Birmingham, Alabama in accordance with the
provisions of Section 15.11 and UABRF shall have the right to raise all of the defenses available
to the University of Alabama at Birmingham.

     15.2
Assignment; Binding upon Successors and Assigns. None of the parties hereto may
assign any of its rights or obligations hereunder (whether by operation of law or otherwise)
without the prior written consent of the other party; provided, however, that any party may assign
its rights and obligations under covenants and agreements to be performed after the Closing in
connection with the sale of all or substantially all of such party’s business. This Agreement will
be binding upon and inure to the benefit of the parties hereto and their respective permitted
successors and assigns.

     15.3
Severability. If any provision of this Agreement, or the application thereof,
becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable,
the remainder of this Agreement will continue in full force and effect and the application of such
provision to other persons or circumstances shall be interpreted so as best to reasonably effect
the intent of the parties hereto. The parties further agree to replace such illegal, void or
unenforceable provision of this Agreement with a valid and enforceable provision which will
achieve, to the extent possible, the economic, business and other purposes of the illegal, void or
unenforceable provision.

-19-

 

     15.4 Entire Agreement. This Agreement (including the Exhibits and Schedules hereto) the
Ancillary Agreements, the documents and instruments and other agreements among the parties hereto
referenced herein and therein, and the exhibits thereto, constitute the entire understanding and
agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede
all prior and contemporaneous agreements or understandings, inducements or conditions, express or
implied, written or oral, between the parties with respect hereto and thereto including, without
limitation, the Letter Agreement. To the extent that any provision of this Agreement conflicts with
any provision of the New License Agreement or the Sponsored Research Agreement between Fluidigm and
UABRF, the applicable provision of the New License Agreement or the Sponsored Research Agreement,
as the case may be, shall control and supersede the applicable provision of this Agreement.

     15.5 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall constitute an original and all of which together shall constitute one and the same
instrument.

     15.6 Expenses.

          (a) The parties shall each pay their own legal, accounting and financial advisory fees and
other out-of-pocket expenses incurred incident to the negotiation, preparation and carrying out of
this Agreement and the transactions herein contemplated, whether or not the transactions
contemplated hereby are consummated.

          (b) Each party shall indemnify the other against, and agrees to hold the other harmless from,
all liabilities and expenses (including reasonable attorneys’ fees) in connection with
any claim by any person for compensation as a broker, finder or in any similar capacity, by
reason of services allegedly rendered to the indemnifying party in connection with the
transactions contemplated hereby.

     15.7 Other Remedies. Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party shall be deemed cumulative with and not exclusive of any other
remedy conferred hereby or by law on such party, and the exercise of any one remedy shall not
preclude the exercise of any other.

     15.8 Amendment. Any term or provision of this Agreement may be amended by a written
instrument signed by Fluidigm, Oculus and UABRF; provided that any term or provision that pertains
only to UABRF and Fluidigm may be amended by a written instrument signed by UABRF and Fluidigm.

     15.9 Waiver. Any party hereto may, by written notice to the other party: (i) waive any
of the conditions to its obligations hereunder or extend the time for the performance of any of the
obligations or actions of another party; (ii) waive any inaccuracies in the representations of
another party contained in this Agreement or in any documents delivered pursuant to this Agreement;
(iii) waive compliance with any of the covenants of the other contained in this Agreement; or (iv)
waive or modify performance of any of the obligations of another party. Except as specifically
contemplated by this Agreement, no action taken pursuant to this Agreement, including without
limitation any investigation by or on behalf of any party, shall be

-20-

 

deemed to constitute a waiver by the party taking such action of compliance with any
representation, warranty, condition or agreement contained herein. Waiver of the breach of any one
or more provisions of this Agreement shall not be deemed or construed to be a waiver of other
breaches or subsequent breaches of the same provisions.

     15.10
Informal Resolution. In the event of any controversy or claim arising under this
Agreement, officers or comparable officials of UABRF, Oculus and Fluidigm shall promptly meet and
attempt in good faith to reach a resolution of such controversy or claim.

     15.11
Mediation. Any controversy or claim between any of the parties hereto arising out
of or relating to this Agreement that is not resolved by the parties within thirty (30) days after
delivery of notice of such controversy or claim, upon written notice of either Fluidigm, Oculus or
UABRF, shall be submitted for resolution by mediation in accordance with commercial mediation
guidelines. Any mediation proceeding shall be conducted in the County of Cook, City of Chicago, in
the State of Illinois. The mediation shall be concluded within a ninety (90) day period after
notice.

     15.12
Notices. All notices and other communications hereunder will be in writing and will
be deemed given (i) upon receipt if delivered personally (or if mailed by registered or certified
mail), (ii) the next business day after dispatch if sent by overnight delivery
service, (iii) upon dispatch if transmitted by facsimile (and confirmed by a copy delivered in
accordance with clause (i) or (ii)), properly addressed to the parties at the following addresses:

	 	 	 	 	 
	 
	 	Fluidigm:
	 	Fluidigm Corporation
	 
	 	 	 	7100 Shoreline Court
	 
	 	 	 	South San Francisco, CA 94080
	 
	 	 	 	Attention:  President
	 
	 	 	 	Facsimile No.: (650) 871-7192
	 
	 	 	 	 
	 
	 	with a copy to:
	 	Fluidigm Corporation
	 
	 	 	 	7100 Shoreline Court
	 
	 	 	 	South San Francisco, CA 94080
	 
	 	 	 	Attention: General Counsel
	 
	 	 	 	Facsimile No.: (650) 871-7195
	 
	 	 	 	 
	 
	 	Oculus:
	 	Oculus Pharmaceuticals, Inc.
	 
	 	 	 	1601 12th Avenue South
	 
	 	 	 	Birmingham, AL 35205
	 
	 	 	 	Attention: B.J. Lehman
	 
	 	 	 	Facsimile No: (216) 361-9495
	 
	 	 	 	 
	 
	 	 	 	and
	 
	 	 	 	 
	 
	 	 	 	Oculus Pharmaceuticals, Inc.
	 
	 	 	 	3201 Carnegie Avenue
	 
	 	 	 	Cleveland, OH 44115
	 
	 	 	 	Attention: B.J. Lehman
	 	 	 	 	Facsimile No.: (216) 361-9495

-21-

 

	 	 	 	 	 
	 	 	 	 	 
	 	 	UABRF:
	 	The UAB Research Foundation
	 	 	 	 	1120G Administration Building
	 	 	 	 	701 20th Street South
	 	 	 	 	Birmingham, AL 35294-0111
	 	 	 	 	Attention: Director
	 	 	 	 	Facsimile No.: (205) 975-5560

     Any party may change its address for such communications by giving notice thereof to the other
party in conformity with this Section.

     15.13 Construction and Interpretation of Agreement.

          (a) This Agreement has been negotiated by the parties hereto and their respective attorneys,
and the language hereof shall not be construed for or against any party.

          (b) The titles and headings herein are for reference purposes only and shall not in any
manner limit the construction of this Agreement, which shall be considered as a
whole.

          (c) Any reference to a “material adverse effect” with respect to any entity or group of
entities means a material adverse effect on the business, assets (including intangible assets),
financial condition, properties, liabilities, results of operations or prospects of such entity.

          (d) Any reference to a party’s “knowledge means such party’s actual
knowledge after reasonable inquiry of its directors, officers and other management level employees
that have responsibility for the referenced matters.

          (e) When reference is made to a Section or Article, such reference shall be to a Section or
Article of the Agreement, unless otherwise indicated.

     15.14 No Joint Venture. Nothing contained in this Agreement shall be deemed or construed
as creating a joint venture or partnership between any of the parties hereto. No party is by virtue
of this Agreement authorized as an agent, employee or legal representative of any other party. No
party shall have the power to control the activities and operations of any other and their status
is, and at all times, will continue to be, that of independent contractors with respect to each
other. No party shall have any power or authority to bind or commit any other. No party shall hold
itself out as having any authority or relationship in contravention of this Section.

     15.15 Absence of Third Party Beneficiary Rights. No provisions of this Agreement are
intended, nor shall be interpreted, to provide or create any third party beneficiary rights or any
other rights of any kind in any client, customer, affiliate, shareholder, partner of any party
hereto or any other person or entity unless specifically provided otherwise herein, and, except as
so provided, all provisions hereof shall be personal solely between the parties to this Agreement.

-22-

 

     15.16 Further Assurances. In connection with this Agreement and the transactions
contemplated hereby, each party shall execute and deliver any additional documents and instruments
and perform any additional acts that may be reasonably necessary or appropriate to effectuate and
perform the provisions of this Agreement and such transactions and the intention of the parties.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

-23-

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set forth
above.

	 	 	 	 	 	 	 
	 	 	FLUIDIGM CORPORATION	 	 
	 	 	 	 	 	 	 
	 	 	By:
	 	/s/ Gajus Worthington	 	 
	 	 	 	 	 	 	 
	 
	 	 	Title:	President & CEO	 
	 	 	 	 	 	 	 
	 	 	OCULUS PHARMACEUTICALS, INC.	 	 
	 	 	 	 	 	 	 
	 	 	By:
	 	/s/ (ILLEGIBLE)	 	 
	 	 	 	 	 	 	 
	 
	 	 	Title:	President & CEO	 
	 	 	 	 	 	 	 
	 	 	THE UAB RESEARCH FOUNDATION	 	 
	 	 	 	 	 	 	 
	 	 	By:
	 	/s/ (ILLEGIBLE)	 	 
	 	 	 	 	 	 	 
	 
	 	 	Title:	Director	 

	 	 	 
	Acknowledged and agreed to	 	 
	this March 7, 2003.	 	 
	 	 	 
	/s/ Dr. Larry DeLucas
 
	 	 
	Dr. Larry DeLucas	 	 

-24-

 

SCHEDULE 4.6

Lawsuit filed by Syrrx, Inc. against Oculus on April 30, 2002 in the United States District Court
for the District of Delaware — Syrrx and Oculus may enter into a settlement agreement to settle the
Lawsuit prior to the Closing under the Agreement; as part of the settlement a judgment or other
order will be entered against Oculus by the court in which the Lawsuit was filed.

 

 

EXHIBIT A

Amended and Restated

Articles of Incorporation of Fluidigm

Superseded by Exhibit 3.1 filed with Registration Statement on April 14, 2008.

 

 

EXHIBIT B

Form of New License Agreement

Superseded by Exhibit 10.9A filed with the Registration Statement on April 14, 2008.

 

 

EXHIBIT C

Form of Sponsored Research Agreement

 

 

EXHIBIT D 

PATENTS AND PATENT APPLICATIONS

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]